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Abstract 
Background: Epidemiological evidence suggests an increased risk of cardiovascular 
associated diseases (CVAD) in both mother and offspring after pregnancies 
complicated by preeclampsia (PE) and diabetes mellitus (DM). The mechanisms 
behind this altered risk in health status are still scarcely unravelled. However, PE, 
DM and cardiovascular diseases (CVD) have several features in common, including 
shared risk factors and similar pathophysiology. Components of the metabolic 
syndrome and endothelial dysfunction, assumed to be closely related to nutritional 
intake and physical activity level, have gained increased attention as unifying 
mechanisms. Foetal programming in utero, as well as birth weight and growth pattern 
in the early postnatal period, may also predict future disease risk. The knowledge 
regarding the relative contribution from ”intrauterine programming” and nutritional 
and metabolic risk factors for the development of cardiovascular health and disease is 
limited, and is a subject for further research. 
Objectives: In the present study we wanted to explore if there are any differences in 
lifestyle factors 5-8 years after delivery between women previously diagnosed with 
PE or DM in pregnancy and women without these complications, and likewise 
between their offspring. The lifestyle factors included in the master thesis were 
nutrition and physical activity. Also, associated risk factors for CVAD, including 
anthropometrics, blood pressure (BP), glucose levels and non-invasive measurements 
of endothelial function were evaluated. 
Subjects: Women previously recruited to a caesarean section biobank in 2001-2004, 
18 of which where diagnosed with PE, 14 of which had DM (8 gestational diabetes 
mellitus (GDM) and 6 DM1) and 9 subjects with uncomplicated pregnancies serving 
as a comparator group, agreed to participate in the present follow-up study, together 
with the child that was delivered and recruited to the original study in 2001-2004. 
Methods: Height, weight, waist and hip circumferences, BP, endothelial function 
(non-invasive technique; EndoPAT) were measured in both mother and child. Both 
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also delivered a urine sample (which was analysed with a urine stix to detect 
glucosuria or proteinuria), and venous blood samples were collected (for future 
analysis in other planned sub studies). An oral glucose challenge test (OGT) was 
performed in the mother, with one reading in the fasting state at baseline and one 
reading 2 hours later after oral intake of 75 mg glucose in 300 ml water. Additional 
clinical information, as well as information regarding nutritional intake and physical 
activity level in both mother and child, were obtained from standardized 
questionnaires. The children also had a cardiac tissue Doppler ultrasound 
examination performed by a paediatrician, but the findings obtained from the Doppler 
study and the endothelial function assessment are not reported in the present master 
thesis (as the analyses will take another 6 months and exceed the scope of this master 
thesis).   
Main outcomes/findings: In the CHASE follow-up study, a higher proportion of 
women and children in the DM-group were overweight and obese compared to the 
other groups. More women in the DM- and PE-group had abdominal obesity 
according to waist-to-hip ratio (WHR) measurements compared to the C-group. We 
also detected significant higher systolic BP and a lower physical activity level in 
women with previous PE or DM. Low intakes of vegetables were identified in all 
groups. However, a larger proportion of children in the C-group followed the fruit 
dietary guidelines of two or more portions a day compared to the DM-group (p = 
0.02) and the PE-group (p = 0.08) of children. Also, a non-significant larger 
proportion of the women in the C-group reported adhering to the fruit dietary 
guidelines compared to the two other groups of women. Women and children in the 
C-group had a higher consumption of cod liver oil and lean milk types as compared 
to the other study groups. 
Conclusion: Preliminary results of the CHASE clinical study have identified aims for 
potential intervention strategies in women and children after pregnancies complicated 
by PE, GDM or DM1. Such intervention could focus on maternal weight reduction 
and prevention of excessive weight gain in the children, increase in physical activity 
level among the women, and advice to increase the consumption of fruit/berries and 
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vegetables, less sugar-sweetened beverages, promotion of lean milk types rather than 
higher fat milk types and possibly the use of cod liver oil supplements. 
Key words: Preeclampsia (PE), diabetes mellitus (DM), gestational diabetes mellitus 
(GDM), cardiovascular disease (CVD), Cardiovascular associated diseases (CVAD) 




AGE: Advanced glycated end products 
AHA: American Heart Association 
BMI: Body mass index 
BP: Blood pressure 
C: Control 
CHD: Coronary heart disease 
CVAD: Cardiovascular associated disease 
CVD: Cardiovascular disease 
Diastolic BP: Diastolic Blood pressure 
DM: Diabetes mellitus 
DM1: Diabetes mellitus type 1 
DM2: Diabetes mellitus type 2 
FFQ: Food frequency questionnaires 
DD: Diet diaries 
GA: Gestational age 
GDM: Gestational diabetes mellitus 
HDL:  High-density lipoprotein 
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Index pregnancy: in the CHASE study: defined as the pregnancy ending with a 
delivery in 2001-4, where the participants in the present CHASE study (2008-9) were 
recruited for the first time to the biobank study. 
IUGR: Intrauterine growth restriction 
LDL: Low-density lipoprotein 
MUFA: Monounsaturated fatty acids 
n-3 PUFAs: Omega-3 polyunsaturated fatty acids 
n-6 PUFAs: Omega-6 polyunsaturated fatty acids 
NO: Nitrogen Oxide 
OGT: Oral glucose challenge test 
OUH: Oslo University Hospital 
PE: Preeclampsia 
ROS: Reactive oxygen species 
BP: Blood pressure 
TAG: Triacylglycerol/ triglycerides 
WFR: Weighed food records 
WHR: Waist/hip-ratio 
WHtR: Waist/height-ratio 
24HR: 24 hour recall 
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1.1 Cardiovascular disease in women and the significance 
of pregnancy complications 
Accounting for one third of all deaths, cardiovascular disease (CVD), which include 
coronary heart disease (CHD), stroke and peripheral vascular disease, is the largest 
single cause of death among women worldwide. In many countries, the mortality 
rates from CVD in women even exceed those of the men’s.  
Most CVD in both women and men is preventable, and modifiable risk factors, some 
of which are also interconnected, include cigarette smoking, poor diet, physical 
inactivity, obesity, hypertension, dyslipidemia, metabolic syndrome and diabetes 
mellitus type 2 (DM 2) (22). 
A risk factor unique to women, is the increased likelihood of developing CVD after 
pregnancy complications such as preeclampsia (PE) and other placental syndromes. 
Whether this reflects a cause and effect relationship, or rather is due to an underlying 
condition that predisposes women to both conditions, is uncertain. An analogous 
situation is the increased risk of developing diabetes mellitus type 2 (DM2) after a 
history of gestational diabetes mellitus (GDM).  
In either case, pregnancy represents an opportunity to identify women at increased 
CVD risk. Given the prevalence of CVD in women, targeting these individuals for 
primary prevention postpartum could be very valuable from a public health 
perspective. As suggested by Newstead et. al, education about healthy lifestyle 
choices could have a positive impact not only on the woman herself, but also on the 
rest of the family members (22, 23, 24). 
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1.2 Preeclampsia 
1.2.1 Clinical picture 
Preeclampsia is a multisystem vascular-related disorder of pregnancy originating in 
the placenta. It is characterized by the occurrence of hypertension (≥140/90 mmHg) 
and proteinuria (≥ 0.3 g/24 h) after 20 weeks of gestation, in a previously 
normotensive woman (1). 
It has been suggested to subdivide the condition into early-onset (< 34 or 37 weeks 
gestation) and late-onset (> 34 or 37 weeks gestation) disease (2).  
About 2-7 % of healthy nulliparous women are affected by preeclampsia (3), with 
approximately 93% of cases developing at 34 weeks gestation or later (4). In Norway, 
the Medical Birth Registry of Norway reported an 3.7% incidence of preeclampsia in 
2004 (89). Most preeclampsia patients are delivered close to term, 2/3 with delivery 
at gestational age (GA) ≥ 37 weeks, and 1/3 with a GA <37 weeks. 
Preeclampsia may further progress to the more severe forms, eclampsia (seizures  
resulting from cerebral edema or cerebral hemorrhage, often with headache and 
visual changes as initial symptoms) and HELLP (hemolysis, elevated liver enzyme 
levels and a low platelet count) syndrome (19-20). 
The offspring can also be adversely affected by the condition. Intrauterine growth 
restriction, preterm birth (most often iatrogen) and foetal death representing the most 
severe complications. (1). 
According to the World Health Organisation (WHO), the hypertensive disorders of 
pregnancy, preeclampsia and eclampsia, collectively accounts for 12 % of maternal 
deaths worldwide (18). Preeclampsia is responsible for approximately 50 000 
maternal deaths annually (90). 
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1.2.2 Long-term implications for both mother and offspring 
Several epidemiological studies have detected an association between a history of PE 
and an elevated risk of future hypertension, stroke, venous thromboembolism, 
ischaemic heart disease and death from any cause. 
The risk seems to be even higher with more severe manifestations of PE, such as 
severe hypertension (systolic BP ≥ 160 mm/Hg and/or diastolic BP ≥ 110 mm/Hg) 
associated with proteinuria, or hypertension associated with severe proteinuria (≥ 
5g/day), multiorgan involvement, PE associated with intrauterine growth restriction 
(IUGR), pre-term birth and foetal death, early onset PE (< 37 weeks gestation) and 
recurrent PE (24-25, 72). 
Offspring of preeclamptic pregnancies might also be at increased risk for future 
CVAD, and several studies have reported higher diastolic and systolic BP in children 
and adolescents subjected to a preeclamptic pregnancy compared to control subjects 
(80-83). However, after adjustment for BMI in one of these studies, and adjustment 
for birth weight, current weight and BMI in another, the observed differences 
attenuated (82-83). 
1.3 Diabetes in pregnancy 
1.3.1 Gestational Diabetes Mellitus 
GDM is defined as glucose intolerance with onset or first recognition during 
pregnancy (26), and women with glucose levels in the top 5-10 % of the population 
distribution meet the diagnostic criteria (27). The condition is associated with insulin 
resistance as well as impaired insulin secretion (68). 
GDM occurs in about 4 % of pregnancies and accounts for nearly 90 % of diabetic 
pregnancies. Women diagnosed in the first half of pregnancy represent a high-risk 
sub group, with an increased risk of obstetric complications, recurrent GDM in 
subsequent pregnancies, and postpartum development of DM2. 
 15
Also, gestational hypertension, PE and essential hypertension seems to be more 
frequent in women with GDM, an association suggested to be linked with insulin 
resistance (26, 68, 71). 
1.3.2 Long-term implications for both mother and offspring 
It is well established that women with a history of GDM are at increased risk for 
subsequent development of DM2. The high prevalence of cardiovascular risk factors 
in these women, such as obesity, insulin resistance, chronic hypertension and 
metabolic syndrome, theoretically place them at increased risk of future development 
of CVD as well (77, 79). 
Intrauterine exposure to diabetes can result in excess foetal growth and macrosomia, 
due to increased maternal glucose transfer across the placenta. Because maternal 
insulin does not cross the placenta, foetal insulin, which itself acts as a growth 
hormone, is produced in elevated amounts. A review including two prospective 
studies that have examined the role of intrauterine exposure to diabetes on childhood 
growth and later risk for obesity and DM2; the Pima Indian Study and the Diabetes in 
Pregnancy Study, supports the evidence that offspring of diabetic pregnancies, 
regardless of maternal diabetes type, are at high risk for obesity and DM2 later in life 
(84). 
A cohort study demonstrated that higher birth weight, and having been born to a 
mother with GDM, both independently predicted increased risk of overweight in 
adolescence. After adjustment for the mother’s own BMI, the association with GDM 
attenuated (85). 
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1.4 What is the association between cardiovascular 
disease, preeclampsia and diabetes mellitus? 
1.4.1 Shared risk factors and similar pathophysiology 
Insulin resistance and the metabolic syndrome 
The metabolic syndrome, which is a spectrum of metabolic abnormalities that are 
related to overweight and insulin resistance, is a key factor underlying atherosclerotic 
CVD and DM2 (30). As defined by The National Cholesterol Education Program 
Expert Panel on Detection, Evaluation, and treatment of High Blood cholesterol in 
Adults (ATP-III) criteria, the metabolic syndrome is characterized by the presence of 
three or more of the following; waist circumference > 102 cm in men and 88 cm in 
women; serum triglycerides (TAG) level ≥ 150 mg/dL (1.69 mmol/L); HDL (High-
density lipoprotein) cholesterol level < 40 mg/dL (1.04 mmol/L) in men and 50 
mg/dL (1.29 mmol/L) in women; BP ≥ 130/85 mmHg; or serum glucose level ≥110 
mg/dL (6.1 mmol/L) (29, 145). Additional components recently recognized, but 
currently recommended only for research purposes, include proinflammatory and 
prothrombotic markers (30). 
During pregnancy, physiological changes occur that results in a transient metabolic 
syndrome characterized by insulin resistance, hyperlipidaemia, up-regulation of the 
inflammatory cascade and an increase in white cell count and coagulation factors. 
Pregnancy complications such as PE and GDM can be regarded as a failure to “the 
pregnancy stress test”, in which there is an exaggerated response to these metabolic 
and vascular changes that normally occurs during pregnancy (31).   
A large retrospective cohort study published in 2005 investigated the association 
between features of the metabolic syndrome and placental dysfunction (including, but 
not limited to PE) in 1.03 million Canadian women with a documented first delivery. 
Any features of the metabolic syndrome were characterized up to 24 months before 
their index delivery. The results indicated that women with pre-pregnancy features of 
the metabolic syndrome had a higher graded risk of placental dysfunction and foetal 
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death (69). A population-based study of 3494 Norwegian women, published in 2007, 
found positive associations between serum levels of TAGs, LDL cholesterol and non-
HDL cholesterol, as well as BP, obesity and waist circumference measured before 
pregnancy, and subsequent risk of PE. These results indicate that risk factors for 
CVD, which are also components of the metabolic syndrome, are evident years 
before the clinical presence of PE (70). Also, a systematic review of 13 cohort 
studies, comprising nearly 1.4 million women, published in 2003, found a strong 
positive association between pre-pregnancy BMI and the risk of PE (73). 
Pre-pregnancy BMI is also associated with the development of GDM, recurrent GDM 
and subsequent development of DM2 (68, 76-77). 
Evidence also indicates that features of the metabolic syndrome can persist 
postpartum in women with previous hypertensive pregnancy (74-75) and GDM (78-
79). 
Endothelial dysfunction 
Physiological function of the endothelium 
The endothelium is the cell-layer lining the internal surface of blood vessels, and 
serves as an interface between the vessel wall and circulating blood. It plays a 
substantial role in regulating vascular homeostasis, tone and structure (33-34). 
Definition 
Endothelial dysfunction is defined as “an alteration of the regular function of the 
endothelium that leads to prothrombotic, pro-inflammatory, proproliferative, and 
proconstrictive activation of the vasculature and is the consequence of insufficient 
repair to removal or functional injury of endothelial cells” (33). 
Endothelial dysfunction in atherosclerosis   
Several hypotheses regarding the phatophysiology of atherosclerosis have been 
proposed, including “the response to retention hypothesis” which suggests 
lipoprotein-matrix interactions as the inciting event in atherosclerosis, “the oxidative 
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modification hypothesis” that focuses on the oxidation of LDL lipids as the critical 
event in atherosclerosis delelopmenet, and “the response to injury hypothesis”. 
According to “the response to injury hypothesis”, endothelial dysfunction is 
recognized as the initial event in atherogenesis, resulting from an injury to the 
vascular wall. This disturbs the balance between vasoconstriction and vasodilation 
and initiates events that are involved in the development of atherosclerosis, such as 
increased endothelial permeability, enhanced adhesiveness of the endothelium to 
leukocytes and platelets and the formation of cytokines (34-35, 91). 
Endothelial dysfunction in preeclampsia 
The patophysiology of PE is not completely understood, but defective placentation 
seems to be an essential event. 
Normal placentation requires that extravillous cytotrophoblasts, a specialized 
population of the outer cell mass of the blastocyst, invade the maternal spiral arteries 
of the uterine wall. During the remodelling of the spiral arteries into large-capacity, 
low-resistance arteries, the extravillous cytotrophoblasts invade the inner part of the 
endometrium (called decidua in pregnancy) and myometrium and replace the smooth 
muscle layer in the vessel wall with a fibrinoid layer. Also, the trophoblast 
temporarily replaces the endothelial lining (92). 
In women who develop preeclampsia, there is a failure of the cytotrophoblasts to 
differentiateinto an endothelial phenotype and the invasion of the myometrium will 
remain shallow. Consequently this will lead to a defective spiral artery remodelling 
with a lack of “physiological change”. The spiral arteries will remain narrow, 
tortuous and thick-walled, with intact smooth muscle cell layer. This non-
transformation of spiral arteries in preeclampsia results in an altered uteroplacental 
circulation and subsequent placental oxidative stress and possibly ischemia, as the 
demands of the growing fetoplacental unit increases (19, 20,21). It is widely believed 
that an oxidatively stressed and possibly ischemic placenta will release 
prothrombotic, proinflammatory, vasoconstrictive and antiangiogenic substances 
(24), which can induce the endothelial dysfunction of the maternal vascular system. 
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There are also findings of increased lipid peroxidation and oxidative stress in the 
placentas of preeclamptic women (141-143). This supports the theory that abnormal 
placentation combined with dyslipidemia can result in the release of free radicals and 
lipid hydroperoxides and thus oxidative stress, believed to cause endothelial damage 
both locally and in the systemic circulation (23, 32). 
In placentas of preeclamptic women, there are often areas of lipid deposition in the 
non-transformed spiral artery walls, called acute atherosis, owing to its similarity to 
the early stages of atherosclerotic lesion with lipid deposition (24). 
Endothelial dysfunction in diabetes mellitus 
Increasing evidence suggest that endothelial dysfunction is a contributor to the 
pathogenesis of vascular disease in DM.  
It has also been proposed that there could be a close link between endothelial 
dysfunction and insulin resistance, as the progression of insulin resistance to DM2 
seems to accompany the development of endothelial dysfunction to atherosclerosis. 
Impaired endothelial function in large arteries is central to the pathogenesis of CVD, 
while endothelial dysfunction in the capillaries and arterioles is a likely key step in 
the development of insulin resistance. (36-38). 
In established diabetes, hyperglycemia plays a significant role in the development of 
endothelial dysfunction and progression of chronic diabetic complications. One of the 
possible pathways involved include the formation of irreversible advanced glycated 
end products (AGE). Adverse effects of AGE to the vasculature includes changes in 
extracellular matrix components, generation of ROS, increased expression of 
inflammatory mediators, growth factors and adhesion molecules. AGE also promote 
the oxidation of LDL. In addition to glycated lipids, oxidized LDL are easily taken up 
by macrophage scavenger receptors, with the subsequent formation of foam cells and 
atherosclerotic plaques (38-40). Circulating AGE was found elevated in pregnancies 
complicated by DM, but not in PE in a previous study from our biobank cohort; 
suggesting a biological heterogeneity (138)  
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1.4.2 Developmental origins of health and disease 
The susceptibility to many late onset chronic diseases has been proposed to be related 
to events in early life. This assumption rests mainly on evidence obtained from 
experimental animal models (7), as well as from epidemiological studies linking low 
birth weight or disproportional foetal growth with later onset CVAD, including non-
insulin dependent DM (5-6). This has led to the hypothesis of “foetal origins” and 
“foetal programming”, which proposes that the foetus make adaptations in response 
to the intrauterine nutritional, metabolic and hormonal milieu. These effects will be 
beneficial for immediate survival. However, if obtained during critical periods of 
development, when developmental plasticity is most pronounced, the effects will also 
persist after birth. In this context, IUGR might result as a consequence of placental 
insufficiency in PE, while macrosomia and congenital malformations might result as 
a consequence of maternal diabetes. In other terms, the foetus has been programmed 
to survive under conditions similar to what was experienced in utero. If a mismatch 
occur between the intra- and the extra-uterine conditions, the resultant phenotype may 
therefore be unfavourable in the long term health perspective (8-11, 86). 
Recent evidence suggest that epigenetic processes (defined as changes in phenotype 
or gene expression caused by mechanisms other than changes in the underlying DNA 
sequence) might be involved in the foetal adaptations in utero, with the consequence 
that these effects also can be passed on to successive generations (12, 13). 
In addition to size at birth, the early postnatal growth pattern also seems to play a role 
for health in later life. As reviewed by Barker, slow growth in foetal life and infancy, 
combined with a rapid increase in BMI after the age of 2 years, is associated with the 
development of CHD and DM2 (14). Other recent publications links the risk of 
becoming obese with certain patterns of growth and weight gain in the first years of 
life. Weight gain during the first 6 months of life (15, 16), and from 2 years onwards 
(16), seems to correlate with later risk of obesity. In a review by Huxley et al., 
evidence also indicates that postnatal catch-up growth is positively associated with 
BP in adult life (17). 
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1.5 Influence of nutrition and physical activity on 
cardiovascular disease and associated conditions 
1.5.1 The metabolic syndrome and its components 
Overweight and obesity 
The metabolic syndrome typically occurs in the setting of overweight or obesity, and 
there seems to be general agreement in the literature that weight reduction should be 
one of the primary approaches in the treatment of this condition (47, 48-50). This can 
be achieved by increasing the physical activity level and by reducing the energy 
content of the habitual diet (49-50, 63-64). 
Insulin resistance and plasma glucose 
Insulin sensitivity often deteriorates in overweight or obese individuals, particularly 
in the presence of visceral adiposity. Thus, loss of body weight can improve insulin 
sensitivity and also exert beneficial effects on the other abnormalities in the metabolic 
syndrome, even if the ideal body weight is not achieved (48-49). 
The type and amount of fat also seems to play a role, with saturated and trans-fatty 
acids reducing insulin action, and unsaturated fat, with strong evidence for 
monounsaturated fat, improving the action of insulin (48-49, 51-53). However, these 
effects are abolished when total fat intake increases from 20 to 40% (48). 
Foods with a high glycemic load, that is; easily absorbed carbohydrates, may 
aggravate glucose intolerance and dyslipidemia. Individuals who are obese and have 
insulin resistance are probably more prone to the metabolic effects of a high dietary 
glycemic load (54). 
Plasma lipid profile 
Type and amount of dietary fat also influences the levels and distribution of plasma 
lipids. Saturated fat is strongly and positively associated with plasma LDL-
cholesterol levels and may also increase BP. Dietary cholesterol is also associated 
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with elevated levels of LDL-cholesterol. n-3 PUFAs reduce serum levels of TAG and 
may lower BP in hypertensive individuals. n-6 PUFAs reduce LDL-cholesterol and 
TAG levels but also reduce HDL-cholesterol levels, while MUFAs reduce LDL-
cholesterol and increase HDL-cholesterol levels, and may exert a reductive effect on 
BP (53). 
Blood pressure 
Although dietary fat may exert some effects on BP, evidence strongly supports that a 
dietary pattern in line with the DASH (Dietary Approaches to Stop Hypertension) 
diet has a pronounced effect in lowering BP. This diet emphasizes a high intake of 
fruits, vegetables and low-fat dairy products and a reduced intake of saturated- and 
total fat and cholesterol. The diet also includes whole grains, nuts, fish and poultry, 
while the inclusion of red meat, sweets and sugar-containing beverages are sparse. 
Especially important is the low salt (NaCl) content of this diet, as salt is an 
independent predictor of elevated BP (55). Weight reduction and moderation of 
alcohol consumption among those who drink alcohol can also lower BP (47). 
1.5.2 Endothelial dysfunction 
In a 2001 review on the topic “Dietary modulation of endothelial function: 
implications for cardiovascular disease”, several dietary factors are highlighted as 
potential modulators. These include: n-3 PUFAs, in part by their in vitro anti-
inflammatory effects and their ability to increase the production of nitric oxide (NO), 
which is an endothelium-derived vasodilator, and to improve hemostatic factors in 
vivo; antioxidant vitamins, with their potential to reduce oxidative stress within the 
body; folic acid, due to its ability to reduce plasma concentrations of homocysteine, 
again related to increased expression of adhesion molecules, platelet aggregation and 
decreased NO-production; and L-arginine, which is the substrate for NO-synthase 
that catalyses the formation of NO (42). 
Although promising, results regarding single nutrients are conflicting and currently 
there are no specific recommendations on the amount of micronutrients, L-arginine or 
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n-3 fatty acids to be consumed, neither in the diet, nor as supplements, for the 
primary prevention of CVD. 
The dietary pattern rather than single nutrients was the focus of a sub-trial based on 
the Nurses` Health study cohort, investigating the effect of diet-quality scores on 
plasma concentrations of markers of inflammation and endothelial dysfunction. Two 
dietary patterns were identified to be strongly associated with lower concentrations of 
biomarkers associated with adverse health effects. The dietary patterns identified 
were both characterized by a high consumption of fruits, vegetables, legumes, nuts, 
whole grains or cereal fiber, less red meat and saturated fat, and a moderate alcohol 
consumption. The main difference between these two diet-quality scores was the 
inclusion of fish in one, and the inclusion of long-term multivitamin use in the other. 
(43). 
Lifestyle interventions, such as dietary modification and physical activity, in adults as 
well as adolescents and children, have also shown to be successful in improving 
arterial function (44-46). The latter finding may be especially important, due to the 
fact that the atherosclerotic process, manifested as so-called fatty streaks, can be 
evident already in early childhood (44). 
1.5.3 Cardiovascular disease 
A review published in 2002 by Hu and Willett, summarizing 147 original articles and 
reviews of epidemiologic studies, metabolic studies and dietary intervention trials of 
diet and CHD, concludes that there is substantial evidence indicating that a high 
consumption of fruit, vegetables and whole grains, using non-hydrogenated 
unsaturated fats as the preferentially source of fats as well as adequate intake of n-3 
PUFAs can offer significant protection against CHD. The review also suggests that 
such dietary patterns in combination with physical activity, avoidance of smoking, 
and maintenance of a body weight in the normal range, may prevent the majority of 
CVD in western populations (56). Among the studies to support this issue, are the 
findings of an inverse association between fruit and vegetable consumption and CVD 
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(57-59), whole grain consumption and ischemic stroke in women (60), fish and n-3 
PUFA consumption and ischemic stroke (61-62), physical activity and CVD events in 
women (65,66-67).  
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2. The CHASE study 
2.1 Background 
The CHASE study is a follow-up study of women and offspring after pregnancies 
complicated by preeclampsia and/or diabetes mellitus, combining clinical and 
molecular findings at delivery with clinical and molecular findings, as well as 
information about nutritional intake and physical activity level, 5-8 years later. 
To our knowledge, few if any publications to date have investigated the nutritional 
intake and physical activity level in mothers and offspring after pregnancies 
complicated by diabetes mellitus or preeclampsia. 
Bearing in mind the epidemiological evidence for an increased risk of CVAD, 
including DM and endothelial dysfunction, in both mother and offspring later in life, 
an antiatherogenic lifestyle, avoiding excessive calories and physical inactivity, 
would presumably be of major health benefit in this at risk population. 
2.2 Objective 
The aim of the CHASE study is to further explore some of the potential mechanisms 
responsible for future development of CVAD, including DM and endothelial 
dysfunction, in both women and children after pregnancies complicated by PE or 
DM, enabling us to later possibly offer specific intervention strategies to optimalize 
health in this population subgroup. 
The master thesis will mainly focus on dietary and physical activity data obtained 
during the first and clinical part of this still ongoing research project. 
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2.3 Hypothesis 
One of our hypotheses was that an “atherogenic” or “obesogenic” lifestyle at least 
partly contribute to the epidemiologically demonstrated increased risk for CVAD 
later in life, in both women and offspring, after PE or DM in pregnancy.  
Based on this assumption, we wanted to investigate whether there are any differences 
between women and offspring of preeclamptic versus diabetic pregnancies, or 
between any of these two groups compared to women and offspring of uneventful 
pregnancies, in any of the following variables: 
1. Anthropometrics 
2. Blood pressure  
3. serum glucose levels 
4. Dietary intake  
5. Physical activity 
Specifically; 
1. Do women and/or children 5-8 years after pregnancies complicated by PE and/or 
DM have a higher BMI, waist circumference, waist/hip ratio and waist/height ratio 
(children) compared to women and/or children who did not have these complications 
5-8 years ago? 
2. Do women and/or children 5-8 years after pregnancies complicated by PE and/or 
DM have a higher BP compared to women and/or children who did not have these 
complications 5-8 years ago? 
3. Do women 5-8 years after pregnancies complicated by PE and/or GDM have a 
persistent glucose intolerance/ hyperglycemia, and are there any differences between 
any of these groups and the control group regarding glucose levels in the fasting state 
and/or 2 hours after an oral load of 75 g of glucose? 
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4. Do women and/or children 5-8 years after pregnancies complicated by PE and/or 
DM have a more unfavourable dietary intake compared to women and/or children 
who did not have these complications 5-8 years ago?  
5. Do women and/or children 5-8 years after pregnancies complicated by PE and/or 
DM have a more sedentary lifestyle compared to women and/or children who did not 
have these complications 5-8 years ago? 
2.4 Subjects 
The clinical basis of the study are 156 women previously recruited to a biobank study 
at Oslo University Hospital (OUH), Ulleval in Oslo, during 2001-2004, due to 
pregnancy complications such as PE (42 women), GDM (39 women), pre-GDM (29 
women, of which 23 women with DMI and 6 with DMII), as well as women with 
uneventful pregnancies (46 women). Most preeclamptic pregnancies were delivered 
prematurely, in contrast to the diabetic and uneventful pregnancies, being delivered 
mostly at term. All women were recruited to the biobank project at time of delivery, 
or close to delivery, and agreed at that time, by signed informed consent, to be 
contacted and asked to participate in potential follow-up studies. 
In the present CHASE study we aimed at recruiting the same mothers and their 
offspring from this pregnancy biobank, 5-8 years after the index delivery. 
Exclusion criteria: current pregnancy, current lactation. 
2.5 Study approvals 
Inclusion in the CHASE study is based on a new voluntary signed informed consent 
from the woman on behalf of herself and her child. The women were explicitly 
informed that they could refuse to participate or later withdraw from the study at any 
time without giving any reason and without any consequences regarding the 
relationship to OUH.  
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The original biobank study is approved by the Regional Committee for Medical and 
Health Research Ethics, Eastern Norway (REK Øst), permission from the Norwegian 
Data Inspectorate (Datatilsynet) has been obtained, and the biobank has been 
approved by the Ministry of Health and Care Services (Helse- og 
omsorgsdepartementet).  
The present CHASE study is approved by the Regional Committee for Medical and 
Health Research Ethics Southern-Eastern Norway (REK Sør-Øst) as well as by the 
Data Inspectorate (konsesjon). Prior to REK evaluation, all formal approvals 
internally at OUH, Ulleval, were provided, including local (Head of Department of 
Obstetrics and Gynaecology) and divisional (Women and Children Division, head of 
research committee) approval, data inspectorate officer (personvernombud), biobank 
officer and formal registration and approval of the project at OUH, Ulleval. The 
CHASE biobank is formally approved by the directorate of Health 
(Helsedirektoratet). 
2.6 Study design 
An invitation to participate was sent to all 156 women from August 2008 (appendix 
1). Those who did not reply after a few weeks, were sent a reminder and/or tried to be 
contacted by phone.  
All women who agreed to participate received two short questionnaires about 
physical activity and nutrition, one for herself and one for her child, which she 
completed before the clinical visit at the hospital. 
The clinical visit lasted for approximately 2-3 hours and included breakfast and time 
to relax and play for the child. 
The woman and her child arrived the hospital after an overnight fast, at 8 am. Both 
delivered a urine sample for urine sticks analysis, and venous blood samples were 
collected for future analysis of routine haematology and potential biomarkers. In the 
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case of the mother, an oral glucose challenge test was also undertaken, with a second 
blood sample 2 hours later for the measurement of serum glucose level.  
A tissue Doppler cardiac analysis was performed in the child by an experienced 
cardiologist paediatrician.  
BP (repeated 3 times after resting), and anthropometrics such as height, weight, waist 
and hip circumferences, were measured in both mother and child, as well as a non-
invasive endothelial function examination, using the “EndoPAT 2000” machine.  
Additional clinical information was given by the mother, on the basis of a 
standardized questionnaire. 
If the women were interested, they could receive feedback on clinical and/or dietary 




Height was measured in centimetres with one decimal, using an altimeter placed on 
the wall, with the participant standing straight, without shoes, and with feet gathered. 
Weight  
The participants were weighed without shoes and heavy clothes. Weight was 
measured in kilograms with one decimal, using a regular electronic scale. 
BMI 
Body mass index (BMI) was calculated according to the formula: weight (in kilo) 
divided by squared height (in meters): weight in kilograms/ (height in meters x height 
in meters). 
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Overweight and obesity in adults was defined as BMI ≥ 25 and BMI ≥ 30 
respectively. 
 Iso-BMI in children was defined using the age- and sex-specific cut off points 
developed by Cole et al. (97).  
Waist circumference  
Waist circumference was measured to the nearest 0.5 cm, using a measuring tape of 
plastic. 
Two different methods were used. In the first method, the waist circumference was 
measured at the narrowest level between the iliac crest and the lowest costa, while in 
the second method, the waist circumference was measured halfway between the iliac 
crest and the lowest costa. The data presented in this thesis on waist circumference 
are based on the latter method. 
Hip circumference  
Hip circumference was measured at the level of the great trochanters (not necessarily 
the widest circumference).  
Waist to hip ratio  
Waist to hip ratio (WHR) was calculated as waist circumference measured at the 
narrowest level between the iliac crest and the lowest costa, divided by hip 
circumference. 
Abdominal obesity 
Abdominal obesity in the women was defined as a waist circumference ≥ 88 cm 
according to the ATP-III criteria, or a WHR ≥ 0.85 according to the World health 
organization (WHO) cut-off points (138).  
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Abdominal adiposity (overweight and obesity) in the children was assessed based on 
age- and sex specific references for waist circumference in Dutch children developed 
by Fredriks et al. (132). 
2.7.2 Blood pressure 
BP was measured manually, with the BP cuff placed on the participant's dominant 
arm. Size of cuff (height) was chosen as approximately one third of upper-arm 
circumference. Three subsequent readings (with cuff in heart level position) were 
performed after the participant had rested for at least five minutes. Average systolic 
and diastolic BP was calculated as the mean of the two last readings. 
2.7.3 Blood samples and OGT 
Fasting blood samples were collected from both mother and child through an 
antecubital arm vein. All children were offered local anaesthesia of the skin prior to 
the test (“Emla plaster”).  
The mothers also performed a 2 hour OGT for detection of any abnormal glucose 
metabolism. According to the WHO (1999) criteria, the fasting serum glucose test 
was defined as elevated if ≥ 6.1 mmol/l and the OGT was defined as abnormal if the 
2 h test was ≥ 7.8 mmol/l (138).  
The OGT method is described in details in appendix 5. 
Urine stix analysis 
Both the women and the children delivered a urine sample during the hospital visit. 
The urine samples were analysed with a urine stix (Bayer™ reagent-stix for urine 
analysis) to detect any glucosuria or overt proteinuria 
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2.7.4 Clinical questionnaire/Clinical form 
A clinical form was also developed to obtain additional information, such as number 
of pregnancies, number of births, menstruation, contraception, lactation, smoking, 
diseases and medications. 
Data regarding blood volumes, urine sticks analysis, BP and anthropometrical 
measurements, were entered into this clinical form as well, by the student in nutrition. 
The standardized clinical information sheet is presented in appendix 2. 
2.7.5 Food frequency and physical activity questionnaires 
In this study we have used two short pre-coded questionnaires about nutrition and 
physical activity, one for the participating mother, and one for the participating child 
respectively.  
The mother received and filled out these two forms after she had agreed to participate 
on behalf of her self and her child. The completion of these forms, which each 
contain three pages, and eight (for the child) and eleven (for the mother) questions 
respectively, was estimated to take approximately 10-15 minutes.  
The children’s questionnaire is, with a few exceptions, identical to a food frequency- 
and physical activity questionnaire previous used and validated against a four-day 
precoded food diary in the Norwegian “UNGKOST 2000” study (87-88). A similar 
food frequency questionnaire (FFQ), used and validated against a 7-day precoded 
food diary in a health survey in Gjøvik, was the basis for the design of the women’s 
questionnaire in the present CHASE study. A validation study on an earlier version of 
the questionnaire used in the health survey in Gjøvik has been published (135).  
Both the women’s and the children’s questionnaire included questions about milk 
intake with different fat percentages, fruit juices, soft drinks with either sugar or 
artificial sweetening, bread with different fibre content, vegetables, fruits, berries, 
meat, fish, bread spreads, as well as the use of supplements, such as cod liver oil and 
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vitamins. Also a question about meal frequency was included. The main differences 
between the women’s and the children’s form, were that the women’s questionnaire 
included questions about alcoholic beverages such as beer and wine, while questions 
about sweets, savoury snacks and fast foods such as pizza, hamburgers and hot dogs 
were included  in the children’s questionnaire. In both the women's and the children's 
questionnaire, frequency alternatives for beverages were; “never/seldom”, “1-3 glass 
a month”, “1-3 glass a week”, “4-6 glass a week”, “1-3 glass a day”, “4-6 glass a 
day” and 7 glass or more a day”, while frequency alternatives for the other food items 
were; “never/seldom”, “1-3 times a month”, “1-3 times a week”, “4-6 times a week”, 
“1 time a day”, “2 times a day”, “3 times a day” and 4 times or more a day”.   
Prior to statistical analysis, the frequency alternatives were recoded into “glass a day” 
and “times a day” for beverages and food items respectively. In the women's 
questionnaire, medium whole grain bread and whole grain bread were recoded into 
one group, while the same was done with sugar sweetened soda and lemonade, as 
well as artificial sweetened soda and lemonade, in the children's questionnaire.  
The questions regarding physical activity among the women comprised how often, 
how long and with what kind of intensity physical activity was performed during the 
last seven days. Two questions about spare time physical activity were included, as 
well as a question about walking/bicycling to or from job/store etc. Frequency 
alternatives were single days. In the children’s questionnaire the questions only 
comprised high-intensity physical activity, and only questions about spare time 
physical activity were included. These two questions were: “how often during a 
week-and how many hours during a week do you perform high intensity physical 
activity?” In contrast to the women’s activity questionnaire, frequency alternatives 
were intervals, ranging from “never” to “every day” and “never” to “seven hours or 
more”. There was also a question about sedentary behaviour, like watching TV or 
playing computer- or video games, with frequency alternatives ranging from “never” 
to “four or more hours a day”.  
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Based on the women's questionnaire, an additional variable “total physical activity in 
hours a week” was computed for statistical analysis.   
The combined physical activity and food frequency questionnaires for mother and 
child are presented in appendix 3 and 4 respectively. 
2.7.6 EndoPAT 2000 
EndoPAT 2000 is a non-invasive RH-PAT (Reactive Hyperemia Peripheral Arterial 
Tonometry) technique. The method is viewed as a reliable and sensitive measurement 
of endothelial function in both adults and children (129, 131-132). 
With use of plethysmography, the PAT signal measures arterial pulsatile blood 
volume changes in the fingertip before and after 5 minutes occlusion of the brachial 
artery, and is a “window” to the arterial endothelial system and the autonomic 
nervous system (144).  
The examination in the CHASE -study took place in a quiet room with dimmed light. 
Only the investigator (the master student or a paediatrician) and the participant were 
present. The participant was resting on a bed during the whole examination, which 
lasted for about 15 minutes. 
Prior to the examination, BP was measured on the dominant arm (as previously 
mentioned under methods; Blood pressure).  
Fingertip probes were then attached to the forefinger on each hand, and the finger on 
the non-occluded arm served as a control registration.  
A blood pressure cuff was placed at the non-dominant arm and inflated to at least 200 
mmHg for 5 minutes. Preceding the occlusion, baseline was measured for at least 5 
minutes (5-6 minutes). Post-occlusion measurement also lasted for at least 5 minutes 
(5-6 minutes). 
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2.7.7 Statistical analysis 
All statistics were performed using the Statistical Package for the Social Sciences 
(SPSS) version 14.0. Comparisons between the groups were analysed using the 
Mann-Whitney test, while the Wilcoxon signed rank test was used in paired analysis. 
Correlations were analysed using Spearman rank correlation coefficient. The level of 
statistical significance was set at P < 0.05. Data are presented as median values and 
values at the 25th and 75th percentile. 
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3. Results 
3.1 The study population 
Data from all women and children enrolled from the beginning of September 2008 to 
the end of February 2009 were included in the present master thesis. More 
participants have been and will be included after this time period, but are not included 
in the present thesis due to time limitation for the master thesis. During this period, 
43 women consented to participate in the CHASE study; 9 of these women were 
categorized in the index pregnancy as belonging to the control group (C, 
uncomplicated pregnancies), 18 to the PE group and 16 to the DM group (8 with 
GDM and 6 with DM1). Two women, one with DM1 and one with GDM, were 
excluded due to current pregnancy, leaving a total number of 41 women and 43 
children (24 girls (55.8 %) and 19 boys (44.2%)). All women in the C-group had a 
Norwegian ethnical background while 88.9 % and 75 % of the women in the PE- and 
DM-group respectively had a Norwegian ethnical background. There were no 
statistical significant differences between the study groups regarding ethnicity. 
Moreover, there were no statistical significant differences regarding distribution of 
higher educational level between the groups of women included. Nearly all of the 
women were non-smokers, and none of the women smoked on a regular basis (data 
not shown). 
Median follow-up time from the index pregnancy to inclusion in CHASE clinical 
study was 7, 6 and 6.5 years for the C-, PE- and DM-group respectively. 
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3.2 Clinical characteristics of the women 
3.2.1 Age 
Median age in years at index delivery and in the CHASE clinical follow-up study was 
33 and 39 in the C-group, 30.5 and 36 in the PE-group, and 32 and 39 in the DM-
group. Differences between the study groups were not significant (table 1 and table 
2).  
3.2.2 Anthropometrics 
Weight measured before or during early index pregnancy (table 1) and in the CHASE 
clinical study (table 2) did not differ between the groups of women. However, during 
this in-between-study period there was a significant higher weight gain of 
approximately 4.7 kg (median value) in the PE group and 3.7 kg in the DM group as 
compared to 0 kg in the C group (P=0.02 for both) (table 3).  
Regarding maternal BMI in the index pregnancy (pre-pregnancy/early pregnancy 
BMI) and BMI at CHASE inclusion, there were no differences between the C-group 
and either the PE- or DM-group, but the DM-group differed significantly from the  
PE-group at both time points (table 1 and 2), with elevated BMIs. Similarly to 
weight, there was also a significant median increase in BMI in both the DM-group 
and the PE-group during the in-between-period, as compared to controls (table 3). 
Waist and hip circumferences were measured in women at inclusion in CHASE 
clinical study. Although no significant differences were found in waist circumference 
between the groups in the CHASE clinical study, there was a significant difference in 
WHR between the C-group (median value: 0.84) and the DM-group (median value: 
0.89) at this time point (table 2). This difference was also significant when comparing 
the C-group to each of the sub groups of the DM-group; DM1 and GDM (data not 
shown). BMI showed a significant correlation to both waist circumference and WHR 
in the women collectively at CHASE-inclusion (P < 0.01), with the strongest 
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correlation to waist circumference (r = 0.91 for BMI and waist circumference, and r = 
0.54 for BMI and WHR respectively). Figure 1 depicts a scatterplot of the correlation 
between BMI and waist circumference in women for the 3 study groups. 
3.2.3 Blood pressure 
Systolic BP at inclusion in CHASE clinical study was significantly lower in the C-
group (median value: 115 mmHg) compared to the PE-group (median value: 119.5 
mmHg) and the DM-group (median value: 121.5 mmHg), while no differences 
existed for diastolic BP (table 2). These differences in systolic BP between the study 
groups were not present when measured before week 20 of the index pregnancy, 
given as mean systolic BP of first 20 weeks (table 1). As shown in table 3, there was 
a significant increase in systolic BP (median increase: 7 mmHg) and diastolic BP 
(median increase: 5 mmHg) from early pregnancy to time of CHASE inclusion in the 
PE-group, as well as in diastolic BP in the DM-group (median increase: 4 mmHg), as 
compared to the C group. Sub analysis of the DM-group showed a significant 
increase in diastolic BP (median increase: 5 mmHg) in the GDM-group, but not in the 
DM1-group. 
3.2.4 Serum glucose values 
Serum glucose levels were only measured among the women in the CHASE study. 
Women with a present known diagnose of DM (eg. DM1) were excluded from taking 
the oral glucose challenge test, and were also excluded from statistical comparisons 
of fasting serum glucose levels between the groups. As presented in table 2, fasting 
glucose levels were significantly higher in the GDM-group (median value: 5.5 
mmol/l) compared to the PE-group (median value 4.8 mmol/l), but not compared to 
the C-group (median value: 4.9 mmol/l). No significant differences were found 
between any of the groups regarding the 2 hour value (table 2). 
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3.2.5 Cut-off values for overweight, obesity, hypertension and 
elevated serum glucose  
At inclusion in the CHASE clinical study, significantly more women in the DM-
group (50 %) had a BMI ≥30 as compared to the C-group (0 %) and the PE-group (11 
%) (table 4). Also, significantly more women in the DM-group had a waist to hip 
ratio ≥ 0.85 as compared to the C-group (92.9 % vs. 33.3 %). The proportions of 
women in each group having a waist circumference ≥ 88 cm and a WHR ≥ 0.85 are 
depicted in figure 2. 
In the GDM-group two women had a fasting serum glucose value ≥ 6.1 mmol/l (25 
%), and one of these women also had a 2-hour value ≥ 7.8 mmol/l. None of the 
women in the PE- or C-group had abnormal serum glucose values (table 4). 
In the PE-group 5 women (27.8 %) had a systolic BP ≥ 130 mmHg, while 2 women 
(11.1 %) had a diastolic BP ≥ 85 mmHg. In the DM-group, 3 women (21.4 %) had a 
systolic BP ≥ 130 mmHg and a diastolic BP ≥ 85 mmHg. One of these women with 
previous GDM and an elevated BP in the CHASE study had a diagnosis of essential 
hypertension already at time of inclusion in the biobank study in 2001-2004. None of 
the women in the C-group were classified as presently having hypertension 
(hypertension was an exclusion criteria in the index pregnancy for the control group). 
However, these differences in BP between the study groups at the time of CHASE 
inclusion, were non-significant (table 4). 
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Age (years) at delivery 9 33.0 28.5, 36.0 18 30.5 27.0, 33.0 16 32 29.0, 35.7 0.347 0.347 0.760 
Pre-pregnancy or early pregnancy 
weight (kg) 
9 69.0 63.5, 77.5 18 65.9 56.5, 72.2 16 72.5 59.0, 94.2 0.433 0.559 0.126 
Pre-pregnancy or early pregnancy 
BMI (kg/m2) 
9 22.5 22.0, 25.7 17 21.9 20.5, 25.1 16 25.7 21.7, 30.6 0.367 0.229 0.049* 
Systolic BP (mmHg) before 
gestational week 20 
9 110.0 110.0, 117.5 18 112.5 110.0, 120.0 16 117.5 110.0, 129.5 0.750 0.185 0.215 
Diastolic BP (mmHg) before 
gestational week 20 
9 70.0 62.5, 71.5 18 67.5 62.5, 70.0 16 70.0 62.7, 81.0 0.542 0.467 0.175 
# Mann-Whitney test, * P= significant < 0.05 
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Age (years) 9 39.0 36.0, 43.0 18 36.0 34.50, 40.0 14 39.0 36.0, 41.2 0.206  0.704 0.207 
Weight (kg) 9 72.0 62.8, 79.8 18 68.8 60.5, 79.5 14 77.7 60.1, 95.9 0.561 0.439 0.220 
BMI (kg/m2)  9 24.6 21.5, 26.7 18 24.0 20.7, 27.5 14 27.9 23.6, 34.8 0.860 0.124 0.025* 
Waist (cm)  9 86.0 78.5, 94.2 18 84.5 79.0, 96.3 14 89.2 78.5, 107.7 0.820 0.477 0.470 
WHR  9 0.84 0.82, 0.86 18 0.86 0.83, 0.91 14 0,89 0.86, 0.92 0.194 0.000* 0.149 
Systolic BP (mmHg)  9 115.0 109.0, 118.0 18 119.5 115.0, 130.0 14 121.5 117.7, 131.5 0.047* 0.010* 0.435 
Diastolic BP (mmHg)  9 71.0 70.0, 74.0 18 70.0 68.7, 80.0 14 72.0 69.5, 81.2 0.916 0.524 0.564 
Glucose, fasting value (mmol/L) ** 8 4.90 4.60, 5.20 18 4.80 4.57, 5.00 8 5.5 4.7, 6.17 0.655 0.138 0.039* 
Glucose, 2 hour value (mmol/L) ** 8 4.35 3.80, 4.82 18 4.00 3.47, 4.60 8 4.55 3.60, 6.8 0.419 0.599 0.278 
# Mann-Whitney test, * P= significant < 0.05, ** women with established DM1 are excluded from the glucose analysis. 
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Figure 1: Correlation between BMI and waist circumference in women (all 
study-groups combined) at CHASE inclusion 
Maternal waist circumference in cm, at 
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Weight (kg) 9 0.0 -2.0, 7.3 18 4.7 -1.4, 9.10 14 3.7 -0.55, 11.1 0.499 0.022* 0.020* 
BMI (kg/m2) 9 0.0 -0.6, 2.7 17 1.2 -0.6, 3.4 14 1.9 0.6, 3.9 0.594 0.031* 0.004* 
Systolic BP (mmHg)  9 -2.0 -7.5, 8.5 18 7.0 0.0, 16.2 14 4.0 -0.7, 8.2 0.722 0.003* 0.074 
Diastolic BP (mmHg)  9 1.0 -4.0, 8.5 18 5.0 0.0, 11.2 14 4.0 0.0, 8.0 0.483 0.004* 0.050* 
# Wilcoxon signed rank test. *P= significant < 0.05. 
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Table 4 : Proportion of women  with values higher than cut-off values for overweight, obesity, hypertension and elevated 






























BMI (kg/m2) 25.0-29.9 (overweight) 9 4 44.4 18 5 27.8 14 3 21.4 0.395 0.252 0.685 
BMI (kg/m2) ≥ 30 (obese) 9 0 0.0 18 2 11.1 14 7 50.0 0.308 0.013* 0.017* 
Waist circumference ≥ 88 cm (obese) 9 4 44.4 18 7 38.9 14 7 50.0 0.786 0.799 0.536 
WHR  ≥ 0.85 (obese)  9 3 33.3 18 12 66.7 14 13 92.9 0.107 0.003* 0.080 
Systolic blood pressure ≥ 130 mmHg  9 0 0.0 18 5 27.8 14 3 21.4 0.086 0.145 0.685 
Diastolic blood pressure ≥ 85  9 0 0.0 18 2 11.1 14 3 21.4 0.308 0.145 0.433 
Glucose, fasting value >6.1** 8 0 0.0 18 0 0.0 8 2 25.0 1.00 0.143 0.030* 
Glucose, 2 hour value > 7.8**  8 0 0.0 18 0 0.0 8 1 12.5 1.00 0.317 0.278 
# Mann-Whitney test, * P= significant < 0.05, ** women with established DM1 are excluded from the glucose analysis.
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Figure 2. Pie charts of the proportions of women in each group having a waist circumference ≥ 88 cm and a WHR ≥ 0.85 
C-group 






























3.3 Clinical characteristics of the Children 
3.3.1 Age 
Median age in years was 6 for all three groups of children, while median age in 
months was 84 in the C-group, 74.5 in the PE-group and 76.6 in the DM-group of 
children (table 5). Further sub division of the DM-group into DM1 and GDM showed 
a statistically significant difference between the children in the DM1-group and the 
children in the C-group regarding age in months (median values 74 and 84 months 
respectively). 
3.3.2 Anthropometrics  
All comparisons of anthropometrical measurements between the main groups of 
children gave non-significant differences (table 5), but a significantly higher waist to 
hip ratio was found in the DM1-group compared to the GDM-group (median values: 
0.96 vs. 0.92). 
3.3.3 Blood pressure 
No differences were found in either systolic or diastolic BP between the groups of 
children (table 5) and all BP were below hypertension thresholds. 
3.3.4 Cut-off values for overweight and obesity 
A non-significant larger proportion of children in the DM-group was overweight 
according to overall (BMI) and central (waist circumference) adiposity cut-off values. 
Only children in the PE- and DM-group were classified as obese according to age- 
and sex specific BMI (1 and 2 children, respectively) and waist circumference (1 and 
1 child, respectively) cut-off values (table 6). 
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Age in years 9 6.0 6.0, 7.0 18 6.0 5.7, 6.2 16 6.0 6.0, 6.7 0.225 0.334 0.744 
Age in months 9 84.0 77.5, 89.5 18 74.5 71.0, 83.7 16 76.6 72.2, 83.5 0.075 0.156 0.666 
BMI (kg/m2) 9 16.6 14.9, 17.8 18 15.9 14.8, 16.9 16 16.9 14.9, 18.5 0.561 0.677 0.408 
Waist in cm 9 59 55.7, 59.7 18 55.7 53.9, 57.6 16 55.2 51.6, 60.5 0.194 0.495 0.849 
WHR  9 0.93 0.89, 0.95 18 0.92 0.90, 0.97 16 0.93 0.92, 0.97 0.940 0.610 0.617 
WHtR  9 0.47 0.44, 0.48 18 0.46 0.44, 0.50 16 0.46 0.44, 0.50 0.705 0.955 0.629 
Systolic blood pressure (mmHg) 9 100.0 90.0, 103.0 17 100.0 95.0, 105.0 16 97.5 90.0, 100.0 0.209 0.600 0.082 
Diastolic blood pressure (mmHg) 9 56.0 52.5, 60.0 17 58.0 55.0, 64.0 16 55.0 55.0, 60.0 0.428 0.907 0.404 
# Mann-Whitney test. 
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Iso BMI (kg/m2) = 25 (overweight) 9 2 22.2 18 2 11.1 16 6 37.5 0.452 0.441 0.074 
Iso BMI (kg/m2) = 30 (obese) 9 0 0.0 18 1 5.6 16 2 12.5 0.820 1.00 0.746 
Waist circumference (overweight) 9 1 11.1 18 3 16.7 16 4 25 0.707 0.414 0.555 
Waist circumference (obese) 9 0 0 18 1 5.6 16 1 6.3 0.480 0.453 0.933 
# Mann-Whitney test
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3.4 Dietary intake among the women 
3.4.1 Consumption of different beverages 
There were significant differences regarding consumption of extra low fat milk and 
skimmed milk between the C-group and the PE-group and between the C-group and 
the DM-group, with a higher consumption in the C-group (table 7). There were 
however no significant differences between the C-group and the GDM-group when 
excluding DM1 cases (data not shown). Regarding alcoholic beverages, women in the 
PE-group had a slightly higher consumption of beer (median value: 0.1 glass/day) 
than the C-group (median value: 0 glass/day) and the DM-group (median value: 0 
glass/day), while women in the C-group had a higher intake of wine (median value: 
0.3 glass/day) compared to the PE- (median value: 0.1 glass/day) and DM-group 
(median value: 0 glass/day) (table 7). The total intake of alcoholic beverages (beer + 
wine) did not differ significantly between the groups (data not shown). 
There was a non-significant difference (P= 0.052) between the PE-group and the C-
group concerning reported intake of sugar containing beverages (median values of 0.1 
glass/day and 0.0 glass/day for PE and C respectively) (table 7). The PE-group had a 
significantly higher consumption of sugar containing beverages than the DM1-group 
(median values: 0.1 glass/day vs. 0.0 glass/day) and a significantly lower 
consumption of artificial sweetened beverages compared to the DM1-group (median 
values: 0.1 glass/day vs. 0.7 glass/day respectively).
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Whole milk 8 0.0 0.0, 0.0 17 0.0 0.0, 0.0 13 0.00 0.0, 0.0 0.215 0.433 0.415 
Low fat milk 9 0.0 0.0, 1.1 17 0.0 0.0, 1.3 13 0.00 0. 0, 0.1 0.608 0.970 0.492 
Extra low fat milk and skimmed milk 9 0.7 0.1, 2.0 17 0.0 0.0, 0.7 14 0.00 0.0, 0.3 0.035* 0.034* 0.928 
Fruit juice 9 0.3 0.0, 1.3 18 0.3 0.2, 0.7 14 0.1 0.0, 0.1 0.428 0.821 0.139 
Sugar sweetened beverages 9 0.0 0.0, 0.1 18 0.1 0.0, 0.3 13 0.0 0.0, 0.7 0.052  0.598 0.055 
Beverages, artificial sweetened 9 0.3 0.0, 1.3 17 0.1 0.0, 0.5 14 0.7 0.0, 2.0 0.638 0.584 0.200 
Beer 9 0.0 0.0, 0.0 18 0.1 0.0, 0.1 14 0.0 0.0, 0.1 0.015* 0.681 0.031* 
Wine 9 0.3 0.1, 0.5 18 0.1 0.0, 0.1 14 0.0 0.0, 0.3 0.028* 0.027* 0.561 
# Mann-Whitney test, * P= significant < 0.05. N varies due to non-answered questions.
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3.4.2 Consumption of different food items 
Significant differences in food items between the main groups of women only existed 
for cod liver oil supplements, with women in the C-group having a higher 
consumption than women in the DM-group (median values: 0.7 times/day vs. 0 
times/day) (table 8). Data on type and amount of bread spreads are not shown .There 
were however no differences between the study groups. Further subdivision of the 
DM-group showed that women in the DM1-group had a significantly lower intake of 
cod-liver oil compared to women in the PE- and C-group (median values: 0.7 
times/day, 0.3 times/day and 0 times/day for the C-, PE- and DM1-group 
respectively), while women in the GDM-group had a significantly lower consumption 
of cheese (median value:0.3 times/day) compared to the C-group (median value: 1.0 
times/day), the PE-group (median value: 1.0 times/day), and the DM1 group (median 
value: 1.5 times/day) and a significantly lower consumption of meat (median value: 
0.3 times/day) than the PE-group (median value: 0.7 times/day). 
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Cod liver oil 9 0.7 0.0, 1.0 17 0.3 0.0, 0.7 14 0.0 0.0, 0.2 0.160 0.016* 0.102 
Vitamin supplement 8 0.3 0.0, 1.0 16 0.1 0.0, 0.6 14 0.0 0.0, 0.5 0.596 0.416 0.502 
White bread 9 0.0 0.0, 0.1 18 0.0 0.0, 0.1 14 0.1 0.0, 0.1 0.394 0.333 0.790 
medium whole grain- and whole grain bread 8 1.1 0.7, 2.0 17 2.1 1.4, 3.0 12 2.0 0.6, 3.0 0.085 0.333 0.625 
Cheese 9 1.0 0.7, 1.0 18 1.0 0.7, 1.0 14 0.7 0.3, 1.2 0.823 0.329 0.279 
Potatoes 9 0.3 0.3, 0.7 18 0.3 0.3, 0.3 14 0.3 0.1, 0.7 0.518 0.893 0.738 
Vegetables 9 1.0 0.7, 1.0 17 1.0 0.7, 1.5 14 0.8 0.7, 1.0 0.643 0.711 0.363 
Fruit/berries 9 1.0 0.7, 2.0 18 0.8 0.7, 2.0 14 0.5 0.3, 2.0 0.559 0.346 0.460 
Fish 9 0.3 0.2, 0.3 18 0.3 0.2, 0.3 14 0.3 0.1, 0.3 1.000 0.502 0.407 
Meat  9 0.3 0.3, 0.5 18 0.7 0.3, 0.7 14 0.3 0.3, 0.7 0.157 0.969 0.145 
# Mann-Whitney test, * P= significant < 0.05. N varies due to non-answered questions.
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3.5 Dietary intake among the children 
3.5.1 Consumption of different beverages  
The children in the C-group had a significantly higher consumption of extra low fat 
milk compared to the PE-group (table 9) and the DM1-subgroup (data not shown). In 
contrast, the children in the PE-group had a higher consumption of low fat milk 
compared to the C-group. No other differences were found in beverage consumption 
between the children, although we found a non-significant lower intake of orange 
juice among the children in the DM-group compared to the C-group (P= 0.073) (table 
9). 
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Whole milk 8 0.0 0.0, 0.5 18 0.0 0.0, 0.7 16 0.0 0.0, 0.2 0.373 0.819 0.463 
Low fat milk 9 0.0 0.0, 0.7 17 2.0 0.2, 2.0 15 0.7 0.0, 0.7 0.018* 0.317 0.090 
Extra low fat milk 8 0.7 0.0, 2.0 15 0.0 0.0, 0.1 16 0.0 0.0, 1.6 0.034* 0.165 0.459 
Skimmed milk 7 0.0 0.0, 2.0 15 0.0 0.0, 0.0 16 0.0 0.0, 0.0 0.076 0.153 0.643 
Orange juice 9 0.3 0.1, 1.3 18 0.3 0.0, 0.7 15 0.1 0.0, 0.3 0.752 0.073 0.114 
Sugar sweetened beverages 7 0.4 0.0, 0.7 17 0.4 0.1, 0.7 16 0.3 0.1, 0.5 0.501 0.866 0.491 
Artificial sweetened beverages 8 0.1 0.0, 0.3 15 0.1 0.1, 0.4 16 0.1 0.1, 0.3 0.469 0.553 0.920 
# Mann-Whitney test, * P= significant < 0.05. N varies due to non-answered questions.
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3.5.2 Consumption of different food items 
Children in the C-group had a higher consumption of cod liver oil compared to 
children in the PE-group (median values: 0.7 times/day vs. 0 times/day) (table 10).  
Sub-group analyses of the DM-group showed that children in the DM1-group had a 
significantly lower consumption of fruit and berries (median value: 1.0 times/day) 
compared to the children in the C-group (median value: 2.0 times/day). No other 
significant differences between the study-groups were detected. 
 56






























Boiled potatoes 9 0.3 0.2, 0.3 18 0.3 0.2, 0.3 16 0.3 0.3, 0.6 0.798 0.320 0.134 
French fries 9 0.0 0.0, 0.1 17 0.1 0.0, 0.1 16 0.1 0.0, 0.1 0.109 0.134 0.923 
Vegetables 9 0.7 0.7, 1.0 18 0.7 0.2, 1.0 16 0.8 0.4, 1.0 0.391 0.859 0.321 
Fruit/berries 9 2.0 1.0, 2.0 17 1.0 0.7, 2.0 16 1.0 0.4, 1.7 0.188 0.070 0.398 
Whole grain bread 9 2.0 1.0, 2.5 18 2.0 1.0, 2.2 16 2.0 0.8, 3.0 0.655 0.907 0.762 
Fish  9 0.3 0.2, 0.3 18 0.3 0.1, 0.3 16 0.3 0.1, 0.3 0.761 0.636 0.827 
Pizza 9 0.1 0.1, 0.3 18 0.1 0.1, 0.1 16 0.1 0.1, 0.1 0.266 0.329 0.926 
Hamburger/hot dogs/kebab  9 0.1 0. 0, 0.2 18 0.1 0.1, 0.1 16 0.1 0.0, 0.1 0.622 0.852 0.738 
Sweets 9 0.3 0.2, 0.3 18 0.3 0.1, 0.3 16 0.3 0.1, 0.3 0.559 0.819 0.696 
Chocolate 9 0.3 0.1, 0.3 18 0.3 0.1, 0.3 16 0.3 0.1, 0.3 0.631 0.899 0.498 
Potato chips etc. 9 0.1 0.0, 0.3 18 0.1 0.1, 0.1 16 0.1 0.1, 0.2 0.819 1.000 0.750 
Peanuts 9 0.0 0.0, 0.1 17 0.0 0.0, 0.1 16 0.0 0.0, 0.1 1.000 0.916 0.911 
Cod liver oil/cod liver oil capsules 9 0.7 0.0, 1. 0 17 0.0 0.0, 0.7 16 0.0 0.0, 0.6 0.040* 0.082 0.952  
vitamins 9 0.0 0.0, 1.0 17 0.3 0.0, 0.7 16 0.1 0.0, 1.0 1.000 0.846 0.955 
# Mann-Whitney test, * P= significant < 0.05.N varies due to non-answered questions.
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3.6 Fruit and vegetable consumption among the women 
and children according to the Norwegian recommendations 
In addition to separate analysis of the responses regarding fruit and vegetable intake, 
these variables were merged according to the Norwegian dietary recommendations of 
2 portions of fruits and berries and 3 portions of vegetables. The proportions of 
women and children following the fruit and vegetable recommendations are shown in 
table 11 and 12 respectively. 
More women and children in the C-group followed the fruit dietary recommendations 
(two portions of fruits and berries) than in the other study groups; 44.4 % of the 
women and 77.8 % of the children in the C-group, 33.3 % of the women and 41.2 % 
of the children in the PE-group and 35.7 % of the women and 26.1 % of the children 
in the DM-group. These differences were only statistically significant between the 
children in the C-group and DM-group (P=0.017). Except for one woman in the DM-
group, none of the women and children in any of the groups reported following the 
recommended intake of 3 portions of vegetables a day. 
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Table 11: Fruit and vegetable intake among the women in the CHASE study compared to the Norwegian recommendations of 



























Fruits (included fruit juice/berries) ≥ 2 portions a day 9 4 44.4 18 6 33.3 14 5 35.7 0.580 0.682 0.890 
Vegetables (included potatoes) ≥ 3 portions a day 9 0 0.0 17 0 0.0 14 1 7.1 1.00 0.423 0.270 
# Mann-Whitney test. N varies due to non-answered questions. 
 
Table 12: Fruit and vegetable intake among the children in the CHASE study compared to the Norwegian recommendations 



























Fruits (included fruit juices/berries ≥ 2 portions a day 9 7 77.8 17 7 41.2 15 4 26.7 0.081 0.017* 0.396 
Vegetables (included potatoes) ≥ 3 portions a day 9 0 0.0 18 0 0.0 16 0 0.0 1.00 1.00 1.00 
# Mann-Whitney test, * P= significant < 0.05. N varies due to non-answered questions. 
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3.7 Physical activity in the women 
We found significant differences between the women in the C-group and the PE-
group, and between the C-group and the DM-group in how often they performed high 
intensity physical activity for a minimum of 20 minutes continuously during the last 
seven days. The women in the C-group reported to do it more frequently than women 
in the other groups (median values: 2 times, 0.5 times and 0 times last seven days for 
the C-group, PE-group and DM-group respectively) (table 13). The difference 
between the C-group and the DM-group also remained statistically significant when 
comparing C-group and the two sub groups of the DM-group separately (GDM and 
DM1) (data not shown). 
The C-group also reported more often performing moderate physical activity in their 
spare time for a total of at least 30 minutes than the DM-group (table 13). When 
compared to each of the DM-groups separately, the difference to the C-group was 
only significant for the GDM-group (data not shown). 
When all the questions about maternal physical activity were summarized, median 
values of total hours spent in physical activity were 3.5, 2.7 and 1.8 in the C-, PE- and 
DM-group respectively. The difference between the C- and DM-group was 
statistically significant (table 13).  
The women were also asked if the last seven days were representative for their usual 
physical activity level. 77.8 % in both the C-group and the PE-group, and 50 % in the 
DM-group reported a representative week, while 22.2 %, 16.7 % and 50 % of the 
women in the C-, PE- and DM-group respectively reported to be less physical active 
than usual. These differences were not statistically significant. 
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P-    
value# 
Walking/bicycling (moderate pace) to or from job/store etc 




3.0 2.0, 6.0 18 3.0 0.7, 5.2 13 2.0 0.0, 5.0 0.866 0.210 0.370 
Spare time physical activity, moderate pace, for min. 30 
minutes total. How many days of the last seven days? 
8 2.0 2.0, 3. 0 18 2.0 1.0, 3.0 13 1.0 0.0, 1.5 0.238 0.021* 0.075 
High intensity physical activity for min. 20 minutes 
continuous. How many days of the last seven days? 
9 2.0 2.0, 3.0 18 0.5 0.0, 2.0 13 0.0 0.0, 1.0 0.011* 0.001* 0.226 
Sum of physical activity during the last 7 days (hours). 7 3.5 3.2, 5.5 18 2.7 1.4, 3.9 13 1.8 0.0, 3.0 0.203 0.035* 0.081 
# Mann-Whitney test, * P= significant < 0.05. N varies due to non-answered questions.
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3.8 Physical activity in the children 
No differences in reported physical activity were found between the main children 
study groups (table 14). There was however a statistically significant more frequent 
physical activity in the C-group as compared to the DM1-subgroup (median values: 
2.5 times/week and 1.7 times/week respectively).  
Hours spent on watching television, playing computer or video games etc. did not 
differ between any of the groups of children (median 0.75 h per day in all study 


































High intensity activity, times/ week 9 2.5 2.5, 5.0 18 2.5 1.0, 5.0 15 2.5 1.0, 2.5 0.490 1.000 0.314 
High intensity activity, hours/week 9 2.5 1.7, 2.0 18 2.5 1.0, 3.1 15 1.0 1.0, 2.5 0.802 0.107 0.169 




4.1 Design and study power 
A scientific weakness of the study is its small sample size, as a small-sized study can 
give low statistical power in some of the study variables. Because we are not aware of 
studies with a similar design, it was difficult to carry out any power calculations prior 
to the CHASE follow-up study, which itself must be regarded as a pilot study.  
The major advantage of the CHASE study is its longitudinal design, making it 
possible to follow the same women and children from delivery to several years 
postpartum. In this way, each woman, each child and each study group of women and 
children serves as their own control measure, as most biomarkers can be measured 
both in biological samples at delivery and 5-8 years postpartum. However, 
information regarding diet and physical activity has only been obtained during the 
CHASE follow-up study, making the quality of this part of the study more vulnerable 
to sample size. This must be taken into consideration when interpreting the results. 
4.2 The study population 
Of the 156 women invited to participate, 43 women (27.6  %) accepted the invitation. 
One woman with DM1 and one woman with prior GDM were excluded due to 
current pregnancy. All of the 43 children were still included, although the total 
number of women was reduced to 41. This is a comparatively small number of 
subjects, and it is therefore uncertain if these women and children are representative 
for the population in question. Especially the number of control subjects is small (n=9 
women and 9 children) compared to the DM-group (n=14 women and 16 children) 
and the PE-group (n=18 women and 18 children), with only half the number of 
subjects compared to latter group. This is not surprising, as women in the C-group 
may not have the same personal interest in participating as one might think women 
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with prior complications in pregnancy may have. I.e. women with pregnancies 
complicated by PE or DM may be more worried about their own future health and 
perhaps also future pregnancies, as well as their offspring’s future health, compared 
to women without such complications during pregnancy. However, population 
characteristics across the groups were quite consistent in terms of age, length of 
follow up from index pregnancy to CHASE clinical study, ethnicity and maternal 
educational level. Also, women recruited to the original biobank study in the index 
pregnancy were not necessarily representative for the whole PE, DM or C group of 
pregnant women. For women with PE, the necessity of performing a caesarean 
section, which was decided independent of their study participation, indicate that 
these women have more severe clinical preeclampsia than the general preeclamptic 
population. Even if our preeclampsia group is not representative for all women with 
preeclampsia, we have recruited the group with potentially greatest research interest, 
as early and severe PE is associated with the largest health consequences for the 
offspring (139). The advantages of such a biobank outnumber the disadvantages, as 
no other methodology would ensure similar biobank material from pregnancies not 
having undergone labour, including maternal and fetal blood and DNA, amniotic 
fluid, as well as placenta/decidual, fat and muscle tissues.  
4.3 Methodological considerations 
4.3.1 Blood pressure and anthropometrical measurements 
Methods regarding BP readings and anthropometrical measurements were 
standardized before the start of the clinical study (as described under “methods”). A 
paediatrician measured the children’s BP, while the master student measured the 
women’s BP and performed all the anthropometrical measurements in both women 
and children. Despite of standardized techniques, it cannot be excluded that 
measurement errors may have occurred. In the case of any errors or imprecise 
measurements, it is likely that these would be systematic and thus similar to all 
groups, as the measurements were performed by the same persons.  
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4.3.2 Diet and physical activity questionnaire 
Numerous methods are available to study an individual’s habitual dietary intake, such 
as weighed food records (WFR), diet diaries (DD)/ Food diaries, 24-hour recalls 
(24HR) and FFQs. WFR is an extensive method where all foods and beverages 
consumed by an individual during a day are measured on scales. This method seems 
to have the best correlation to objective biomarkers of dietary intake, and thus 
considered the most valid of these dietary assessment tools. As with WFR, DD is a 
prospective and extensive dietary assessment method. In this method however, each 
day’s dietary intake is estimated on the background of unit portions and/or photos or 
illustrations of portion sizes. The length of these registrations (WFR and DD) varies, 
but typically covers several days, weekdays and weekends included. In contrast to the 
prospective methods, 24HR is a recollection of the participant’s dietary intake during 
the last 24 hours and is typically interviewer-administered. Repeated 24HR likely 
reduces day-to-day variability that is easily lost with a single 24HR, and is better 
correlated to biomarkers of dietary intake than is a single 24HR. Another 
retrospective instrument is the FFQ. This method is shown to be weaker associated 
with biomarkers of dietary intake than the other methods, but is cost-effective and is a 
commonly used tool to assess dietary intake in large population studies. These 
questionnaires can be long or short, depending on the purpose of the study. If the 
questionnaire addresses the amount of each food item consumed, in addition to 
frequency, the FFQ is defined as semi-quantitative (136). In the CHASE study we 
have used short FFQs developed and validated at the Department of nutrition, 
University of Oslo, Norway. These questionnaires only cover some indicator food 
items and not the whole diet, and the frequency alternatives are limited. In this way, 
results may be somewhat imprecise, seasonal variation is easily lost and nutrient 
content and total caloric intake are impossible to estimate. However, validation 
studies have demonstrated a significant correlation between increasing intake 
measured with a four-day precoded food diary and the FFQ used among the children 
in our CHASE study, and a seven day precoded food diary and the FFQ used among 
the women in our CHASE study respectively (87, 135). In the children’s 
questionnaire, beverages, fruit and vegetables had the highest correlations to the 
 66
precoded food diary. Infrequently eaten food items, such as pizza and potato chips, 
had weaker correlations. In the women’s questionnaire, ten out of sixteen food items 
had a correlation to the precoded food diary of at least r = 0.5. The questions 
concerning meat for dinner and the consumption of vegetables in the women’s 
questionnaire had the weakest correlation to the precoded food diary. The simple 
FFQs used in the present CHASE study are also easy to complete and much less time 
consuming than the more extensive registrations. Because of the comprehensive 
clinical examination of both mother and child in the CHASE-follow-up study, these 
limited questionnaires were our preferred method in order to reduce any burden such 
reporting of diet may cause on the participants, especially the mother, as most of the 
children in our CHASE study were too young to administer any dietary registrations 
on their own. In this way we also believed that compliance to the study recruitment 
and fulfilling the questionnaires would increase. Due to the small sample sized cohort 
available, this factor was of high importance when deciding which method would be 
the most appropriate. Concerning physical activity, indicator questionnaires were 
likewise also chosen instead of more extensive self reporting methods, or direct 
measurements of physical activity or physical fitness. Physical activity questionnaire 
is in general an inexpensive and applicable tool to assess physical activity in large 
samples. However, the most important limitation of this method is its subjective 
component, and results may be prone to over-or underestimation. Questionnaires are 
also less suited for children, due to the complexity in answering these forms. Thus, 
the women in our CHASE study completed both their own and their child’s 
questionnaire about diet and physical activity. Alternative methods for physical 
activity assessment include activity monitors such as pedometers and accelerometers, 
and heart rate monitoring. Methods such as indirect calorimetry and the doubly 
labelled water method are less applicable on a large study cohort. Accelerometer-
based monitors are considered valid in estimating overall physical activity, but are 
inappropriate in monitoring complex movements, upper body movements, cycling or 
movements on a graded terrain. Heart rate monitoring is an indirect measure of 
physical activity, but is only valid for moderate- to vigorous activities, as the 
relationship between heart rate and oxygen consumption is not linear during rest or 
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low-intensity activities, and is easily confounded by factors such as caffeine, 
smoking, stress and other factors not related to physical activity (137). 
4.3.3 Statistical analyses  
All data were analysed using non-parametric tests, such as the Mann-Whitney U test 
and the Wilcoxon signed rank test. However, a few of the continuous variables 
showed a normal distribution, and were initially analysed with the student t-test. The 
results didn't differ significantly between the two methods used, and for simplicity we 
decided to present all data based on non-parametric tests.  
A large number of variables have been tested in the present master thesis. When 
analysing several variables there is a certain risk that significant differences between 
the groups may occur in some of the study variables simply by chance. Although a 
lower level of statistical significance could have reduced this risk, for instance using 
the Bonferroni correction (140), there is also a risk that actual differences between the 
groups would not have been detected if a lower level of significance was chosen. 
4.4 Main findings 
4.4.1 Anthropometrics 
A relatively large proportion of the women were classified as overweight in all 
groups according to BMI (44.4 %, 27.8 % and 21.4 % in the C-, PE- and DM-group 
respectively). However, significant more women in the DM-group (50 %) were 
classified as obese (BMI ≥ 30), compared to 11.1 % in the PE-group and none in the 
C-group. Data from a larger health survey conducted in five counties in Norway in 
2000-2003, showed that 26.6 % and 13.2 % of women 30 years of age were 
overweight and obese, respectively. In the same population, women aged 40 and 45, 
32.7 % and 25.5 % were overweight and obese, respectively (94). The proportion of 
overweight women in our study population therefore resembles these larger 
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population data, while the proportion of obese in our study differs with a much larger 
percentage obese women in the DM-group.  
In the CHASE clinical study there was no difference in the proportion of women 
having abdominal obesity when waist circumference was used as an indicator, and 
waist circumference had a high correlation to BMI. However, when the WHR was 
compared between the groups, significant more women in the DM-group were 
identified with abdominal obesity. Also the percentage of women in the PE-group 
classified as having central obesity increased when the WHR was used as an 
indicator, while this was the other way around in the C-group of women. This finding 
is striking, suggesting that fat deposition may be different between these groups, with 
a more even fat distribution in the C-group of women. 
Several studies have elucidated the correlation between overweight and obesity and 
risk of CVAD. Results have varied regarding which anthropometrical measurement is 
best at identifying subjects at increased risk. In a cross-sectional survey in 2000, 
Dalton et al. showed that WHR had the strongest correlations with CVD risk factors 
before age adjustment in a national sample of 11 247 Australian adults, but after 
adjustment for age, waist circumference, WHR and BMI had similar correlations with 
CVD risk factors (95). In 2005, Yusuf et al. conducted a case-control study of 
approximately 15 000 cases of first myocardial infarction, and nearly 15 000 age- and 
sex-matched controls. Study participants were enrolled from 52 countries, 
representing several ethnic groups. They found that BMI and WHR were directly 
related to risk of myocardial infarction. However, in contrast to BMI, WHR remained 
a statistically significant risk factor after adjustment for BMI and other risk factors 
(96). Similar results were obtained by Canoy et al. who prospectively examined the 
association between body fat distribution and coronary heart disease in a cohort of 
about 24 500 men and women aged 45-79 years. They found that the abdominal 
obesity indices; WHR and waist circumference, were more predictive of CHD than 
BMI. Hip circumference was shown to be inversely related to risk of CHD, after 
adjustment for waist circumference, BMI, and CHD risk factors (97).  
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Overweight and obesity are also related to risk of DM2. Both overall obesity as 
assessed by BMI, and central obesity as assessed by waist circumference and WHR, 
are associated with increased risk of DM2. Results have also indicated that there may 
be an additive effect of the combination of overall and central obesity (98-99).  
Also, a relationship between adverse pregnancy outcomes and anthropometrical 
measures has been explored. As reviewed by Siega-Riz et al., there is a clear 
association between BMI above the normal range and pregnancy complications 
including pregnancy induced hypertension, PE and GDM (100). However, the 
distribution of body fat may also play a role. In a cohort of 198 control women and 26 
women with PE, Yamamoto et al. showed that WHR, irrespective of overall 
adiposity, was a significant predictor of the development of PE on stepwise multiple 
regression analysis (101). Also Soonthornpun et al. found that women with previous 
PE had higher waist circumferences and WHR than age- and BMI-matched C-
subjects, although BMI were not significantly different between the two groups 
(102).  
We also found a statistically significant difference in maternal pre-pregnancy BMI of 
the index pregnancy between the DM-group and the PE-group, with a higher median 
BMI in the DM-group (25.7 kg/m2 compared to 21.9 kg/m2), but there was no 
significant difference between the C-group and the two other groups of women. No 
significant difference was found between the three groups of women regarding 
weight gain during pregnancy (data not shown), but during the in-between study 
period from to the index pregnancy and the inclusion in CHASE clinical study, there 
was a significant median change in maternal weight (+ 4.7 kg and + 3.7 kg in the PE- 
and DM-group respectively) and BMI (+ 1.2 and + 1.9 in the PE and DM-group 
respectively) in both the PE-group and the DM-group, and the difference in BMI 
between the two groups remained statistically significant. We do not know whether 
these changes were due to weight gain after the index pregnancy, an excessive 
retention of gestational weight or both. In a prospective cohort study of 540 healthy 
adult women with singleton pregnancies, Olson et al. showed that gestational weight 
gain, postpartum exercise frequency and change in the amount of foods consumed, 
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were significantly associated with weight change from early pregnancy to 1 year 
postpartum. These factors were associated with postpartum weight retention as well 
as major weight gain (103).  
In the CHASE clinical study we found that both women with PE or DM during the 
index pregnancy were less physical active than the C-group of women. No data exists 
on dietary- and exercise habits before the index pregnancy, and whether there have 
been any major changes in one or both of these lifestyle factors is unknown. During 
the postpartum period of 5-8 years, median changes in weight and BMI in our study 
were small, and the clinical relevance is therefore questionable. If however, such 
differences attenuates further in the years to come, the differences in risk for CVD 
between the PE-/DM- and the C-group will increase similarly. 
Also a comparatively large proportion of the children examined in the CHASE 
clinical study was overweight or obese. Similar to the women, more children in the 
DM-group had a BMI corresponding to overweight and obesity compared to the PE-
group and C-group of children. These differences were however not significant. 
According to age and sex specific BMI cut-off points, 37.5 %, 11.1 % and 22.2 % of 
the children were classified as overweight in the DM-group, PE-group and C-group 
respectively, while the proportions classified as obese was 12.5 %, 5.6 % and 0 % for 
the DM-, PE- and C-group of children respectively. By contrast, the proportion of 
overweight 9 year old in a nation-wide survey in Norway was 12.8 % and 14.7 % for 
boys and girls respectively. Likewise, the proportion of obese was 2.8% and 4.7 % 
for boys and girls respectively (110). Thus, our findings indicate that the prevalence 
of overweight among children after diabetic pregnancies are higher than in the 
general population as well. 
A BMI in the upper percentiles in adolescence has been related to increased risk of 
both cause specific mortality, including circulatory system diseases and ischemic 
heart disease, and total mortality in adulthood. Whether this is connected to long-term 
obesity is unknown. However, childhood obesity seems to be a predictive factor for 
adult obesity (105-106).  
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Overweight and obesity are also highly important risk factors for the development of 
DM2 in children and adolescents, probably through the association with insulin 
resistance. If DM2 is diagnosed already during childhood, typical long term 
complications of DM, such as neuro-, retino- and nephropathy and atherosclerotic 
CVD, will also develop at earlier stages in life (104). 
Similar to adults (130), evidence indicates that children with central obesity have a 
higher risk of metabolic disturbances such as an unfavourable lipid profile, elevated 
BP and insulin resistance (128). In the present CHASE study, a non-significant higher 
proportion of children in the DM- and PE-group were overweight and obese 
according to waist circumference measurements, compared to the C-group.  
4.4.2 Blood pressure 
In the CHASE clinical study we found a significant higher maternal median systolic 
BP in both the PE-group and the DM-group compared to the C-group. Systolic and 
diastolic hypertension according to ATP-III criteria was identified among a 
proportion of women in the PE- and the DM-group, but not in the C-group. 
Compared to C-subjects, higher BP, either systolic BP or both systolic and diastolic 
BP post-delivery in women with PE has been described by others. In three similar 
clinical follow-up studies of BP in women with a history of PE, the mean or median 
interval between delivery and follow-up was 1-6 years. Mean systolic- and diastolic 
BP in women with previous PE ranged from 118 to 122 mmHg, and 76-81.5 mmHg 
respectively among these studies, while mean systolic- and diastolic BP in C-women 
ranged from 109- to117 mmHg, and 70-74 mmHg respectively (102, 107-108). Smith  
et al. (108) reported  the prevalence of hypertension one year postpartum in the PE-
group as 20.3 % with a systolic BP ≥ 130 mmHg and 38.6 % with a diastolic BP ≥ 85 
mmHg, while the corresponding numbers were 1.4 % and 5.7 % in the C-group.  
Vhor and Boney also found that from 5 to 11 years post-delivery, women with a 
history of GDM had higher systolic BP than women without a history of GDM, 
ranging from 121.8 to 124.9 mmHg in women with previous GDM, and from 117 to 
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118 mmHg in women without previous GDM. They also reported that by 11 years 
postpartum, 30 % of the women with previous GDM had systolic hypertension 
(systolic BP ≥ 130 mmHg), compared to 14 % among the controls (109). 
These results are consistent to our findings in the CHASE clinical study. Although 
Smith et al. reported a much higher percentage of diastolic hypertension among 
women with previous PE compared to our findings, these results may not be quite 
comparable taken into consideration the differences in years of follow-up from 
delivery, as well as possible differences in the study population. 
4.4.3 Serum glucose levels 
In the CHASE clinical follow-up study we identified elevated fasting values of serum 
glucose in two women (25 %) with previous GDM, indicating abnormal glucose 
tolerance. One of these two women also had elevated serum glucose values after the 
2-hour glucose challenge test, but the levels were not compatible with diabetes. 
However, it is estimated that approximately 30 % of subjects with abnormal glucose 
tolerance after 10 years will develop DM2 (133). 
A study by Lauenborg et al., investigating the prevalence of the metabolic syndrome 
in a large Danish cohort of women with previous diet treated GDM and women with 
uncomplicated pregnancies at median 9.8 years of follow-up (4-23 years), detected 
impaired fasting glucose among 11.0 % of the previous GDM-group, and 4.3 % in the 
comparator group. The total prevalence of glucose intolerance in the GDM group was 
67.6 %, of which 39.9 % had established DM, compared to 19.2 % and 3.3 % 
respectively in the comparator group. Median follow-up in our CHASE study was 6.5 
years (5-8 years), and it is possible that a longer follow-up time would be more 
appropriate in detecting the risk of developing glucose intolerance or diabetes 
postpartum in women with prior GDM. However, Lauenborg et al. have earlier also 
demonstrated a 40 % incidence of DM in Danish women with a history of diet treated 
GDM at a median of 6-7 years post-delivery (134). Again, our small-sample sized 
study must be taken into consideration when interpreting these results. 
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Even though we did not find any differences in median values of serum glucose 
levels between either of the two pregnancy complication groups and the C-group, we 
cannot exclude that there could be differences in insulin levels between the groups. 
Normal serum glucose values in women with a history of PE have been reported by 
others, despite concomitant findings of elevated serum insulin levels (107-108). 
Serum insulin measurement will be performed later in the CHASE study, following 
completed patient inclusion and data collection. 
4.4.4 Dietary intake 
To our knowledge there are few if any publications regarding dietary intake in 
women  and their offspring several years after pregnancies complicated by PE or DM. 
Based on the epidemiological increased risk of developing CVAD after such 
complications in pregnancy, we were especially interested to find out whether there 
are any indications that diet may be a contributing factor.  
Our Chase study results showed a little variation in reported dietary intake across the 
groups of women and children, with a few exceptions. The most striking findings 
were differences in the consumption of sugar-containing soft drinks, lean milk types, 
cod liver oil and fruit/berries. 
Sugar-sweetened soft drinks 
Our results showed that women in the PE-group had a significant higher consumption 
of sugar-sweetened beverages compared to the DM1-subgroup of women and a 
borderline significant higher consumption compared to the C-group.  
Clausen et al. also found that a higher intake of sucrose during the second trimester of 
pregnancy was associated with increased risk of PE. Among the women with a high 
intake of sucrose, sugar-sweetened soft drinks accounted for nearly 70 % of the total 
sucrose intake, and sugar-sweetened soft drinks was independently related to the risk 
of PE-development. The authors suggested that the association between a high intake 
of sucrose and the increased risk of PE could be due to the suppressive effect of 
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hyperglycemia on endothelium-dependent vasodilation, or by a worsening of the 
dyslipidemia, which is also associated with endothelial dysfunction (111). Our 
finding, which indicates that the postpartum intake of sugar-sweetened soft drinks is 
higher among women with previous PE compared to C-subjects, is therefore 
interesting, as endothelial dysfunction is also linked to the pathogenesis of CVD and 
DM. 
Sugar-sweetened soft drinks is one of the major sources of added sugar in the 
Norwegian diet, and a high consumption of these types of beverages may also be a 
contributing factor in the development of overweight and obesity (112). Some 
evidence indicate that energy consumed as liquid is less satiating as energy consumed 
as solid food (47), and this could be a likely explanation. A reduction in the 
consumption of sugar-sweetened soft drinks is therefore recommended and highly 
desirable (112).  
Despite the differences observed in our study, the amounts consumed by the PE-
group are relatively small, corresponding to less than a glass a week. Underreporting 
is a general problem of self-reported dietary intake such as FFQs (127), and the actual 
intake could theoretically be somewhat higher. We do not know whether this 
underreporting, if present, should differ between the study groups. We found no 
differences in educational level between the study groups, which could also 
theoretically influence the reporting patterns of dietary intake and physical activity. 
In contrast, compared to women in the PE-group, women in the DM1-group reported 
a higher intake of artificial sweetened soft drinks. A likely explanation for these 
differences between the PE- and DM1-group, is that DM1-subjects, due to their 
underlying disease and need for insulin treatment, avoids food items with a high 
glycemic index, such as sugar containing soft drinks.  
Milk consumption 
Women in the C-group reported a significant higher intake of lean milk types (extra 
low fat- and skimmed milk) compared to the two other groups of women. Also the 
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children in the C-group had a significant higher intake of extra low fat milk compared 
to the children in the PE-group and the DM1-subgroup of children. Because of the 
high percentage of saturated fat in cow's milk, it is generally recommended to choose 
lean milk types. The women and children with a lower intake of extra low fat- or 
skimmed milk did not replace this lower consumption with whole fat milk type, but 
children belonging to the PE-group had a significantly higher intake of low fat (1.5 % 
fat) milk as compared to the C-group. 
Several studies have investigated the possible protective effect of milk and dairy 
products on hypertension and stroke incidence, with some, but not all, showing an 
inverse relationship. Dietary minerals such as Ca, Mg and K, as well as milk peptides, 
have been suggested to exert antihypertensive effects, but the knowledge in this area 
is still limited (113-115). In the DASH-diet (Dietary Approaches to Stop 
Hypertension) guidelines, advice to increase the consumption of low fat dairy 
products is included (55).  
Also, the potential protective effect of calcium on PE prevention has been 
investigated in several studies (116-117). Results from these studies are however 
inconsistent, and the issue seems to be controversial. 
Cod liver oil supplement 
In the present study we found that women in the C-group had a significantly higher 
consumption of cod liver oil supplement compared to women in the DM-group, while 
comparisons between the children showed a statistically significant higher intake of 
cod liver oil in the C-group compared to the PE-group. 
Cod liver oil contains long chain n-3 fatty acids. Long chain n-3 fatty acids have been 
shown to exert beneficial effects on CVD risk factors, such as reducing plasma levels 
of TAGs, BP, platelet aggregation and inflammation, improving endothelial function, 
lipoprotein profile and have also been related to a decreased risk of CVD and 
cardiovascular mortality in both epidemiological- and intervention studies (118-120). 
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Therefore, it is of interest that the potentially beneficial cod liver oil is more often 
consumed by women and children with the lowest risk of CVD (the control group).  
Along with fish oil supplements, such as cod liver oil, oily fish is the main dietary 
source of long chain n-3 fatty acids in the Norwegian diet. We didn’t find any 
differences in fish consumption among the groups in the CHASE study. We do not 
know however, if there are any differences in the consumption of oily fish among the 
groups, as the question about fish consumption was not sub-divided into oily- and 
lean fish in the FFQs. Also, the question about fish consumption only covered fish for 
dinner, not fish used on sandwiches or in other form. Hence, although the use of cod 
liver oil supplements was different between the groups, it is difficult to conclude 
whether there are any significant differences in the total intake of long chain n-3 fatty 
acid. 
Fruit and berries  
A non-significant higher proportion of women and children in the C-group followed 
the Norwegian dietary recommendation of two or more portions of fruits and berries 
a day compared to the other CHASE study-groups. However, with the exception of 
the C-group of children, where nearly 78 % consumed the recommended amounts, 
less than 50 % of the women and children within each group followed these 
guidelines. Children in the DM-group had the less frequent consumption of fruit and 
berries, and the difference to the C-group was statistically significant.  
Using data from a nation-wide survey in Norway (“UNGKOST 2000”), Frost 
Andersen et al. showed that children and adolescents (four-year-olds and pupils in the 
fourth and eighth grades) consumed less than half the recommended intake of fruit 
and vegetables. Results from this survey also showed that total diet quality increased 
with increasing intake of fruit and vegetables. A positive correlation was found 
between fruit and vegetable intake and dietary content of all vitamins and minerals 
and dietary fiber, as well as a negative correlation between fruit and vegetable intake 
and energy content from sugar and saturated fat (88). Because of the limitations of 
the FFQs used in our study, such correlation analyses could not be performed. 
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However, the children’s questionnaire used in the present CHASE study was 
validated against a pre-coded food diary in the same study (“Ungkost 2000”), and 
fruit and vegetables were among the food items that showed the best correlations to 
the pre-coded food diary. It is therefore likely that the quality of the diet is decreased 
among the children with low intakes and increased among the children with higher 
intakes in our CHASE study as well. Similar correlations between fruit and vegetable 
intake and diet quality were also found in a study by Dennison et al., who examined 
the fruit and vegetable intake among 168 healthy US children 2 and 5 years of age 
(121). 
A recent publication by Holt et al. also showed that fruit and vegetable consumption 
was inversely related to markers of inflammation and oxidative stress in youth. This 
association has previously been reported in adults as well (122). 
4.4.5 Physical activity 
In the present CHASE clinical study, we found that women in the C-group more 
often performed high-intensity physical activity compared to women in the PE- and 
DM-group. Women in the DM-group were the less physical active of the three study-
groups, also regarding moderate-intensity activity.  
Physical activity confers a wide range of health benefits and is central to the 
prevention and treatment of obesity, hypertension and other CVAD (63, 123-124). 
Interestingly, in the CHASE study, women in the PE-group and the DM-group also 
had higher systolic BP compared to women in the C-group, and women belonging to 
the DM-group were more obese compared to women in the C-group. However, 
physical activity is also inversely associated with cardiovascular- and all-cause 
mortality in both men and women independent of other risk factors (125). 
Evidence also indicates that physical activity before and during pregnancy may lower 
the risk of developing pregnancy complications such as GDM and PE. Physical 
activity, through means of pre-pregnancy weight reduction and the prevention of 
excessive weight gain during pregnancy, may also reduce the risk of other obesity 
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related complications of pregnancy, such as delivery of large for gestational age- and 
macrosomic babies, caesarean section and instrumental delivery (126). Because of the 
increased recurrence risk in women with previous GDM and PE, increased 
postpartum exercise could possibly have a beneficial impact on subsequent 
pregnancies as well. 
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5. Conclusion  
1. Anthropometrics 
Preliminary results of the CHASE study have identified a higher obesity rate among 
women in the DM-group, as assessed by BMI and WHR, compared to the other 
CHASE study-groups and women in the general population. There were no 
differences in waist circumference between the women study-groups. Although we 
did not find any statistical significant differences in any of the anthropometrical 
measurements among the children, a comparatively high proportion of children of 
diabetic pregnancies was classified as overweight according to age- and sex-specific 
BMI and waist circumference calculations.  
2. Blood pressure 
The CHASE study further demonstrated that women with PE or DM in a pregnancy 
5-8 years ago have higher systolic BP, but not diastolic BP, as compared to control 
subjects of the same study cohort. There were however no differences in BP between 
the groups of children included. 
3. Serum glucose 
There were no differences in median values of serum glucose, neither in the fasting 
state, nor 2 hours after an oral glucose challenge test between the C-group and either 
of the PE- or GDM-group of women in the CHASE study-cohort. Two women with 
previous GDM were however identified with impaired glucose tolerance and will be 
subject to follow up by own general practitioner.  
4. Dietary intake 
The results of the present CHASE study showed a little variation in reported dietary 
intake across the main groups of women and children, with a few exceptions; 
differences in the consumption of fruit, lean milk types and cod liver oil supplement 
(more women and children in the C-group), and sugar-sweetened soft drinks (more 
women in the PE-group) were the main findings. 
5. Physical activity 
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The CHASE study also demonstrated that women with pregnancies complicated by 
PE or DM 5-8 years ago, were less physical active compared to women with 
uncomplicated pregnancies 5-8 years ago. Differences in physical activity or 
inactivity (screen-time) were not demonstrated among the children study-groups. 
 
Although we did not find major differences in dietary intake among the groups of 
women or children, it is still likely that women and children in the PE and DM cohort 
would benefit from improvements in diet. Since they run an epidemiological 
augmented risk of CVAD as compared to women and children of uneventful 
pregnancies, it would probably  be beneficial if their food intake and physical activity 
level were at least as good as in the control group, and that the obesity rate was not 
higher than in the general population (ideally lower). The CHASE study has 
identified potential intervention possibilities such as weight reduction in the women 
and prevention of excessive weight gain in the children, increased consumption of 
fruit- and vegetables, promoting the use of lean milk types rather than higher fat milk 
types, decreasing the intake of sugar-sweetened beverages and possibly also advice 
regarding cod liver oil supplement. Women with previous PE or DM in pregnancy 
should also receive advice to increase physical activity. Whether information 
strategies after a pregnancy complicated by PE and/or DM is effective in reducing 
these risk factors for CVD, as well as really reducing the incidence and severity of 
CVD in the women and their offspring, remains to be explored. 
Further studies on the biological samples and endothelial function studies in the total 
CHASE cohort will identify whether the differences between the study groups in 
anthropometrics (such as BMI, WHR etc), BP and environmental factors (food intake 
and physical activity) are associated with differences in circulating biomarkers of 
endothelial health and function. 
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Forespørsel om deltakelse i forskningsprosjektet 
”CHASE: cardiovaskulær helse hos mor og barn etter svangerskapskomplikasjoner” 
 
Bakgrunn og hensikt. Dette er et spørsmål til deg om å delta i en forskningsstudie for å forstå mer om 
sammenhengene mellom svangerskapsforhold og senere helse for mor og barn. Du som spørres om å delta i 
denne studien, var deltaker i en forskningsstudie på Fødeavdelingen ved Ullevål universitetssykehus for 5-8 år 
siden, der det ble samlet prøver fra deg og fra barnets navlestrengsblod (det siste dersom du ble 
keisersnittsforløst). Både kvinner med normale graviditeter, gravide med diabetes og svangerskapsforgifting ble 
inkludert i studien, og vi fikk tillatelse til å ta kontakt med deg senere for å spørre deg om å delta i en 
oppfølgingsstudie. Det er Ullevål universitetssykehus som også er ansvarlig for CHASE-studien.  
 
Hva innebærer denne studien? Deltakelse i ”CHASE”-studien innebærer en helseundersøkelse av deg og ditt 
barn (det som ble født da du deltok i studien på Ullevål 5-8 år siden), inkludert en blodprøve av dere (barnet får 
vanlig bedøvelseskrem før blodprøven fra albuevenen). I tillegg vil vi benytte opplysninger fra den forrige 
studien du var med i. Før undersøkelse på Ullevål fyller du ut et kort kost- og aktivitetskjema for deg selv og 
barnet ditt (tar ca 10 minutter). Ved undersøkelsen på Ullevål tas blodprøvene, en smertefri 
ultralydundersøkelse av barnets hjerte (av barnelege, tar ca 15 minutter), samt at blodstrømmen i fingertuppen 
til barnet og deg selv måles smertefritt (tar ca 15 minutter). Undersøkelse gjøres en dag som passer best for deg, 
på morgenen før dere spiser frokost. Dere vil få servert frokost etter blodprøvetakingen. For å ha god tid til 
pauser og lek, setter vi av ca 2 timer til samtale og undersøkelser totalt. Dersom du ønsker tilbakemelding på 
kosthold, fysisk aktivitet og vanlige helseparametre (blodtrykk, kroppsmasseindex, blodsukker etc), kan du 
avtale ny samtale (på Ullevål eller per tlf.) med masterstudenten i ernæring tilknyttet prosjektet. Mer 
informasjon om hva undersøkelsen innebærer, finner du i kapittel A (side 2). 
Mulige fordeler og ulemper. Du og barnet ditt vil ikke ha noen spesielle fordeler av å delta i studien, 
bortsett fra at du får tilbakemelding om vanlige helseparametre og kostholdsveiledning, dersom du ønsker 
dette. Dersom du ønsker å delta i studien, innebærer dette praktisk denne undersøkelsen på Ullevål 
av deg og barnet ditt. Vi forskere har håp om å finne faktorer som kan være av betydning for forståelse av 
mekanismer bak helse- og sykdomsutvikling hos mor og barn etter svangerskapskomplikasjoner. Vi håper 
at økt kunnskap kan bidra til å styrke positiv helseutvikling samt å forebygge sykdom på lang sikt.  
 
Hva skjer med blodprøvene og informasjonen om deg og barnet ditt? Prøvene tatt av deg og ditt barn og 
informasjonen som registreres om dere skal kun brukes slik som beskrevet i hensikten med studien. 
Opplysningene og prøvene vil bli behandlet uten navn og fødselsnummer eller andre direkte gjenkjennende 
opplysninger. En kode knytter dere til deres opplysninger og prøver gjennom en navneliste. Det er kun 
autorisert personell knyttet til prosjektet som har adgang til navnelisten og som kan finne tilbake til dere. 
Blodprøvene vil oppbevares med kopling til din og barnets identitet på Ullevål inntil de er oppbrukt. Etter 
senest 20 år vil kopling til din og barnets identitet slettes, og prøver og informasjon oppbevares etter dette 
anonymt. Vi ber også om å kunne innhente relevante opplysninger fra journalene deres ved UUS og andre 
sykehus, samt fra offentlige registre, beskrevet i Kapittel B, side 3). Det vil ikke være mulig å identifisere deg 
eller ditt barn i resultatene av studien når disse publiseres.  
Frivillig deltakelse. Det er frivillig å delta i studien. Du kan når som helst og uten å oppgi noen grunn trekke 
ditt samtykke til å delta i studien, uten at det får konsekvenser for behandling av deg eller ditt barn på 
sykehuset. Dersom du ønsker å delta, undertegner du samtykkeerklæringen på slutten av informasjonsskrivet 
(Kapittel C, side 3), og sender den tilbake til sykehuset i vedlagte frankerte konvolutt. Vi vil så ta kontakt med 
deg per telefon for å avtale tid for undersøkelsen. Vi vil kontakte per tlf kvinner som ikke har svart på denne 
henvendelsen innen 3 uker, for å sikre oss at denne forespørselen er kommet frem. 
Mer viktig informasjon om studien finnes i Kapittel A og B (side 2 og 3).  
Vennlig hilsen leger/forskere på Kvinneklinikken og Barneklinikken ved Ullevål universitetssykehus:  
Overlege dr. med Annetine Staff (prosjektleder, gynekolog, førsteamanuensis),  
prosjektkoordinator Marie Skogstad, 
doktorgradsstipendiat Anja Lee (barnelege) og masterstudent i ernæring Anne Stine Kvehaugen. 
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Kapittel A- utdypende forklaring om hva studien innebærer 
• Bakgrunnsinformasjon for studien: Studien forsøker å finne bakenforliggende faktorer som kan forklare 
hvorfor noen kvinner etter svangerskap har endret risiko (enten lavere eller høyere enn gjennomsnittet) for å 
utvikle hjerte- og karsykdom i voksen alder. Forskning tyder på at forhold i svangerskapet kan være viktige 
både for mor og barns helse senere, samt at ernærings- og aktivitetsforhold spiller en rolle. Vi vet at kvinner 
som har hatt svangerskapsdiabetes eller svangerskapsforgiftning har en litt høyere risiko enn kvinner som 
har hatt svangerskap uten disse komplikasjonene til å utvikle hjerte- og karsykdom eller diabetes. De aller 
fleste kvinnene som har gjennomgått disse svangerskapskomplikasjonene utvikler imidlertid IKKE hjerte- 
og karsykdom eller diabetes i voksen alder. Vi kjenner dårlig til de biologiske mekanismene som har 
betydning for sammenhengen mellom svangerskapet og senere helse- og sykdomsutvikling. Denne 
forskningsstudien forsøker å finne noen av disse sammenhengene. 
• Hvem kontaktes for å delta i CHASE-studien? Ca 160 kvinner kontaktes i dette forskningsprosjektet. 
Alle kvinnene deltok ila 2001-2004 i en forskningsstudie ledet av førsteamanuensis, overlege, dr. med. 
Annetine Staff ved Kvinneklinikken, Ullevål universitetssykehus. I den forrige forskningsstudien ga dere oss 
forskere tillatelse til å kunne ta kontakt ved en senere anledning for en oppfølgingsstudie. CHASE er en slik 
oppfølgingsstudie, der vi altså på nytt ønsker å rekruttere dere til forskning for å gi svar på viktige 
helsespørsmål. Fordelen med denne nye undersøkelsen er at vi kan knytte informasjon fra svangerskapet og 
fødselen med informasjon fra dere flere år etterpå, dvs vi kan følge samme kvinne og barn over tid. 
• Dekking av eventuelle utgifter: Parkeringsutgifter på Ullevål samt eventuelle reiseutgifter kan avtales 
refundert når vi kontakter deg (per telefon) for tid til undersøkelsen av deg og barnet ditt. 
• Videre undersøkelser etter CHASE-studien: Dersom du eller barnet mot formodning skulle vise tegn på 
sykdom som bør utredes nærmere, slik som høyt blodsukker eller hjertesykdom, så vil vi sørge for videre 
oppfølging i helsesystemet. 
• Undersøkelser, blodprøver og annet de inkluderte mødrene og barna gjennomgår: 
Før undersøkelsen på Ullevål:  
Mor og barn: Et kort kost- og aktivitetsskjema for deg og barnet ditt fylles ut av deg før undersøkelse 
på Ullevål (tar ca 5-10 minutter). Disse skjemaene sender vi deg når du har sendt inn det signerte 
samtykket til å delta (Kapittel C, side 3). 
Under undersøkelsen på Ullevål (max 2 timer totalt, inkludert pauser og tid til lek): 
• Mor og barn: Vekt og høydemåling, innhenting av vanlig klinisk informasjon (sykdom, 
medikamenter, vektutvikling etc). 
• Mor og barn: Det tas blodprøve av deg og barnet ditt (prøven tas etter hudbedøvelse for barnet). 
Dere skal møte fastende til undersøkelsen, dvs ikke ha spist eller drukket 6 timer før undersøkelsen. 
Vi foreslår derfor at dere møter til undersøkelsen kl 8, slik at dere kan spise den frokosten dere 
ønsker hos oss etter at blodprøvene er tatt.  
• Bare mor: For de kvinnene som har hatt svangerskapsdiabetes eller svangerskapsforgiftning 
(preeklampsi), tilbyr vi en blodsukkerbelastning. Denne ”sukkerbelastningen” kan avdekke 
begynnende tegn til diabetesutvikling og diabetes. Dette er rutinetilbud til alle som har hatt 
svangerskapsdiabetes. Også kvinner med normale svangerskap kan få utført denne testen, hvis de 
ønsker det. I praksis betyr det at vi legger inn en kanyle i albuevenen slik at vi bare stikker deg en 
gang. Fra denne kanylen trekker vi blodprøver 2 ganger: første gang når du kommer om morgenen 
(fastende), så 2 timer etter at du har drukket et glass med sukkervann. Etter dette fjerner vi kanylen, 
og du kan få spise frokost hos oss.  
• Både mor og barn: Blodstrømmen i fingertuppen måles smertefritt med et apparat (tar ca 15 min). 
• Bare barn: En barnelege med lang erfaring vil foreta ultralydundersøkelse av barnets hjerte (tar ca 
15 minutter), en helt smertefri undersøkelse. 
Før, under eller etter undersøkelsen på Ullevål:  
• Mor og barn: Dere får 2 glass til urinprøve (1 til deg og 1 til ditt barn). Disse prøvene kan leveres på 
undersøkelsesdagen eller senere (vi avtaler hva som passer deg best per tlf).  
• Mor: Dersom du ønsker tilbakemelding på kosthold, fysisk aktivitet og vanlige helseparametre 
(blodtrykk, kroppsmasseindex, blodsukker etc), kan du avtale ny samtale (på Ullevål eller per tlf) 
med ernæringsfysiologi-studenten i prosjektet. 
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Kapittel B - Personvern, biobank og dine rettigheter 
Personvern: Opplysninger som registreres om deg oppbevares slik beskrevet på side 1. Som i forrige 
undersøkelse du deltok i på Ullevål (som gravid), ønsker vi mulighet til å følge din og barnets helse over tid, ved 
å få din tillatelse til å kople studieresultater mot forskriftsregulerte registre (Kreftregisteret, Fødselsregisteret, 
Dødsårsaksregisteret) og mot journaler i andre sykehus, for opplysninger som er relevante for denne studien. 
Ullevål universitetssykehus (adm. direktør) er databehandlingsansvarlig for dine personopplysninger. 
Informasjon til og samtykke fra barnet ditt til å delta i forskningsprosjektet: Siden barnet ditt (det som 
ble født da du var med på forskningsstudien, ila 2001-2004) er så ungt, vil ditt samtykke for å delta i studien 
også gjelde for barnet ditt. Vi har et enkelt informasjonsskriv med tegninger om hva som skal gjøres i 
undersøkelsen tilpasset de eldste barna i studien, som du kan vurdere om ditt barn skal få. Dersom ikke 
blodprøver er brukt opp når barnet ditt er myndig (18 år), vil vi ta kontakt med deg for at ditt barn selvstendig 
skal bestemme om vi kan bruke prøver og informasjon videre.  
Biobank: Blodprøvene som blir tatt av deg og ditt barn, og informasjonen utledet av dette materialet, vil bli 
lagret i en forskningsbiobank ved Ullevål universitetssykehus. Hvis du sier ja til å delta i studien, gir du også 
samtykke til at det biologiske materialet og analyseresultater inngår i biobanken. Biobankkoordinator Roger 
Bjugn ved Ullevål universitetssykehus er ansvarlig for biobanken (ansvarshavende), og prosjektleder Annetine 
Staff kan kontaktes ved evt. spørsmål. Biobanken planlegges å vare til prøvene er oppbrukt. Etter senest 20 år 
vil materialet og opplysninger bli anonymisert etter interne retningslinjer.  
Behandling av materiale og opplysninger hos andre: Hvis du sier ja til å delta i studien, gir du også ditt 
samtykke til at avidentifiserte prøver og opplysninger sendes til samarbeidende forskere i Norge og i utlandet, 
som bidrar til CHASE-studiens undersøkelser. Ullevål er fremdeles ansvarlig for prøvene og opplysningene, 
dersom de sendes til samarbeidende forskere. Opplysninger som identifiserer deg eller ditt barn vil ikke 
utleveres. Noen land utenfor EU/EØS har lover som ikke tilfredsstiller europeisk personvernlovgivning, men 
dersom prøver sendes dit, vil ikke opplysninger om helseforhold følge prøvene, sammenkoplingen mellom 
helseopplysningene og de biologiske prøvene vil skje i Norge. Ved henvendelse til prosjektleder vil du kunne få 
en oppdatert liste over hvilke samarbeidspartnere dette omfatter.  
Rett til innsyn og sletting av opplysninger om deg og sletting av prøver: Hvis du sier ja til å delta i 
studien, har du rett til å få innsyn i hvilke opplysninger som er registrert om deg. Du har videre rett til å få 
korrigert eventuelle feil i de opplysningene vi har registrert. Dersom du trekker deg fra studien, kan du kreve å 
få slettet innsamlede prøver og opplysninger, med mindre opplysningene allerede er inngått i analyser eller 
brukt i vitenskapelige publikasjoner. Dersom du senere ønsker å trekke deg eller har spørsmål til studien, kan 
du kontakte prosjektleder Annetine Staff (22119800) på Kvinneklinikken, Ullevål. 
Forsikring: Alle som deltar i studien er dekket av norsk pasientskadeerstatningsordningen (www.npe.no). 
Informasjon om studieresultater: Dersom du ønsker tilbakemelding om kosthold, fysisk aktivitet og 
helseparametre som kroppsmasseindeks og blodsukker, kan du avtale samtale (på UUS eller per tlf) med 
ernæringsfysiologi-studenten knyttet til prosjektet, for en samlet gjennomgang. 
____________________________________________________________________________________ 
Kapittel C: Samtykkeerklæring 





(Signert av prosjektdeltaker, dato) 
 
Jeg kan enklest kontaktes for avtale om 
undersøkelsestid på telefon 
(mobil og evt fasttelefon nummer): 
 
--------------------------------------------------  
Dersom du ønsker å vite mer, er det bare å kontakte oss for ytterligere informasjon, 
ved prosjektkoordinator Marie Skogstad (tlf  93 48 42 47,mail riog@uus.no), Ullevål universitetssykehus.  
 
Dersom du ønsker å delta i undersøkelsen, vennligst returner dette informasjonsskrivet i signert form i 
vedlagte frankerte konvolutt. Du beholder selv en kopi av informasjonsskrivet (”Kopi til 
studiedeltaker”). For å være sikker på at vi har rett kontaktadresse for deg, vil vi forsøke å kontakte deg igjen 
en stund etter at vi har sendt deg dette brevet, dersom vi ikke har hørt fra deg. 
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KLINISKE DATA 
CHASE-nummer (CM1-149), nummerering 
etter us-dato
skjema fylles ut av studieansatte: hvem: 
MORS  KLISTREMERKE MORS NAVN OG FØDSELSNUMMER
Mors diagnose (sett ring) ved inklusjon i 
sectiobiobank-prosjektet UUS                
2001, 2002, 2003, 2004: PE C DM+PE
Mors alder i år i dag Siste menses dato:
Graviditeter siden sist?
Nå: dag i menssyklus (dag 1 er første mensdag, normalt 
28 d syklus)
Fødsler siden sist?
Prevensjonsbruk (hva): p-pille, IUD (kobber eller 
hormonspiral= Levonova/Mirena), kondom, sterilisert 
(mannen eller damen)t J/N
Totalt (i dag): Gravida (Antall 
graviditeter) Gravid nå? J/N
Totalt (i dag): Para (antall fødsler etter 
uke 16)
Siste graviditet/fødsel, hvor mange mnd siden siste 
gang?
Ammer? (mnd siden siste partus?) J/N
Andre sykdommer: J/N Hvilke sykdommer:
Sykdom etter sectio-biobank-deltakelse 
(i 200_____)? J/N
Medikamentbruk nå? J / N  Hvilke medikamenter?
HVIS DIABETES noen gang:
Røyker nå J / N stk/dag: DM        før/    under/    etter svangerskap?
Snus nå J / N stk/dag: Dia type I (antall år) J / N
Dia type II (antall år) J / N
Mors høyde (cm) Har hatt GDM i et svangerskap?  (antall ganger?) J / N
Mors vekt (kg), t-skjorte og truse på sist HbA1C (Dato:               )   
Mors livvidde, smalest (cm) Nå: Kostregulert diabetes bare? J / N
Mors livvidde, mellom nederste ribbe og 
hoftekam (cm) Nå: perorale antidiabetika? J / N
Mors hoftevidde (hoftekamknutenivå) 
(cm) Nå: insulinregulert diabetes? J / N
Insulinmengde pr døgn:
Mors BT i dag, hvert mål nærmeste 2 
mmHG  (3 målinger etter 5 min hvile, 
sittende, bruk høyre arm, de 2 siste 
målinger teller og brukes til å regne et 
matematisk gj.snitt) Mansjettbredde ca 
1/3 av overarmvidden. Syst Diast hurtigvirkende (IE)
BT1 langsomtvirkende (IE)
BT1 Total insulinbruk (IE)
BT3
URIN STIX MOR; (skriv alltid protein: 0, +1, 
+2, eller +3. anfør ellers bare om andre 
variabler slår ut på stix)
Antall rør med  urin i fryser (x rør):





DM:    DM1,   DM2,    GDM-kost,   GDM-insulin
Hvilke sykdommer: Antall ganger preeklampsi
Hvis + urin, send prøve til mikrobiol us, UUS, fyll ut rekv skjema med Annetine Staffs klistremerke. 
Skriv på skjema at urin stix positiv på … Kvinnen frisk, utelukke Urinveisinfeksjon. Ingen 
antibiotikabruk pågående. Gi Annetine beskjed, Annetine følger opp prøven og gir svar til mor.
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edta-cellerest J/N
Paxgene rør, antall nunc?
Heparinrør til Glutathion
Barnets Navn og fødselsnummer
CHASE-nummer: CB1-149
Barnets kjønn M/F
Barnets alder i år i dag
Barnets alder i mnd i dag
Barnets vekt i dag (kg)
Barnets høyde  i dag (cm)
Barnets smaleste livvidde i dag (cm)
Barnets  livvidde i dag(målt midt mellom 
nederste ribbe og hoftekam)(cm)
Barnets hoftevidde (hoftekam) i dag 
(cm)
SYST DIAST
Barnets BT i dag (3 målinger etter 5 min 
hvile, sittende, bruk høyre arm, de 2 
siste målinger teller). Mansjettbredde ca 
1/3 av overarmvidden
Hvis + urin, send til micribiol 
us med Heidi Ramstads 
rekvmerke og gi henne 
beskjed, hun følger opp 
pasienten.
Hvis + urin, send til micribiol us med Heidi Ramstads rekvmerke og 
gi henne beskjed, hun følger opp pasienten.
BT1 Gi ved positiv urin beskjed til barnets mor om at urinen sendes til us og at hun får svar fra barnelegen uansett fun
BT2
BT3
URIN STIX BARN (skriv alltid protein: 0, 
+1, +2, eller +3. anfør ellers bare om andre 
variabler slår ut på stix)
Antall rør med  urin i fryser (x rør):
Barnets medikamentbruk i dag
Frisk etter fødsel? JA
NEI-spesifiser
Innhentet barnets vektpercentilskjema fra mor, evt hun henter fra helsestasjon?











Hvis + urin, send prøve til mikrobiol us, UUS, fyll ut rekv skjema med Heid Ramstads klistremerke. 
Skriv på skjema at urin stix positiv på … Barnet frisk, utelukke Urinveisinfeksjon. Ingen 
antibiotikabruk pågående. Gi Heidi beskjed, Heidi følger opp prøven og gir svar til mor.
Gi ved positiv urin beskjed til barnets mor om at urinen sendes til us og at hun får svar fra barneleg




Kort spørreskjema om kosthold og fysisk aktivitet for 
kvinnen (mor) som er med i CHASE-studien 
 





































Skjemaet består av 3 sider  







Vi spør om dine spisevaner slik de vanligvis er. Vi er klar over at kostholdet varierer fra dag til dag. 
Prøv derfor så godt du kan å gi et ”gjennomsnitt” av dine spisevaner.  
Ha det siste året i tankene når du svarer. Der du er usikker, anslå svaret. 
 
1. Hvor mye drikker du vanligvis av følgende drikker? 
Sett ett kryss for hver drikke. ( ½ liter = 3 glass)                   
              
                                                                        Drikker           1-3 glass     1-3 glass     4-6 glass     1-3 glass     4-6 glass    7 glass el 
 Aldri/sjelden   pr mnd        pr uke         pr uke         pr dag         pr dag        mer pr dag 
Helmelk (søt og sur), glass  
 
Lettmelk (søt og sur), glass     
                          
Skummet melk, ekstra lett lettmelk  
(søt og sur), glass    
 
Juice, most, glass          
                                 
Sukkerholdig leskedrikk (brus, saft), 
glass 
 
Kunstig søtet leskedrikk (lett brus, saft), 
glass 
  
Øl, glass  
 
Vin, glass                                            
                                                                                                      
         
                                                                                                      
         
                                                                                                      
        
         
                                                                                                      
        
                                                                                                      
         
         
                                                                                                      
         
 
                                                                                                      
 




2. Hva pleier du å smøre på brødet? (sett kun ett kryss) 
 
 
Bruker ikke          Meierismør       Bremykt        Brelett        Melange, Per,                    Soyamargarin                  Lettmargarin 
smør/margarin                                                                        Soya margarin i pakke      i beger (eks Soft Flora)    (eks Soft Light) 
     




3. Hvis du bruker smør eller margarin på brødet, hvor mye pleier du å smøre på per skive? 
(sett kun ett kryss) 
 
En porsjonspakning på ca 12 g rekker til omtrent           1         2        3         4          5         skiver 






4. Hvor ofte bruker du vanligvis? (sett ett kryss for hvert kosttilskudd) 
 
                                              Aldri/         1-3             1-3            4-6          1 gang       2 ganger     3 ganger      4 ganger   
                                              Sjelden      ganger       ganger       ganger      pr dag        pr dag         pr dag        eller flere  




                                                                                                     
 
                                                                                                     
 
                         
 
                                  
5. Hvor ofte spiser du vanligvis de følgende matvarer i løpet av en uke? (Sett ett kryss for hver 
matvare) 
                                                                               Aldri/       1-3          1-3           4-6         1 gang     2 ganger    3 ganger     4 ganger   
                                                                              Sjelden     ganger     ganger     ganger    pr dag      pr dag        pr dag        eller flere  
                                                                                               Pr mnd     pr uke     pr uke                                                          pr dag                
  
Loff/ fint rundstykke, skiver 
 




Ost som pålegg og i retter, skiver 
 
  Poteter i en eller annen form f.eks kokt potet, 
 potetmos, stekt potet, bakt potet  
Grønnsaker, for eksempel rå grønnsaker,  
salater, kokte grønnsaker, stekte grønnsaker, 
grønnsaksretter, grønnsaksjuice 
 
 Frukt og bær, alle typer som f.eks  
frisk frukt/bær, kompott, hermetikk, juice osv. 
 
Fisk til middag 
 
Kjøtt til middag 
                                                                                           
 
                                                                                           
 
                                                                                           
     
                                                                                           
 
                                                                                           
 
 




                                                                                           
 
 
                                                                                           
 
                                                                                           
 
 
                     
Måltider 
 
6. Hvor ofte pleier du å spise følgende måltider i løpet av en uke? (sett ett kryss for hvert måltid) 
 
                                      Aldri/           1 gang       2 ganger       3 ganger       4 ganger        5 ganger        6 ganger        Hver                         









                                                                                                                     
  
                                                                                                                      
  
                                                                                                                     
  





7. Hvor mange ganger pleier du å spise ett eller annet utenom hovedmåltidene (f eks godteri, 
frukt, brødskive) i løpet av dagen? 
 
                                                  1 gang                2 ganger              3 ganger              4 ganger               mer enn 4        
                               Sjelden                  om dagen           om dagen            om dagen            om dagen              ganger om dagen 
 






8. Hvor mange av de siste 7 dager har du gått eller syklet til eller fra jobb, butikk eller 
lignende i  moderat  tempo i totalt minst 30 minutter? (Bolker på 10 minutters varighet teller, 
dvs at 3x10 minutter fører til 30 minutters aktivitet.) 
 
                      Ingen           1 dag          2 dager          3 dager          4 dager          5 dager           6 dager               Hver  
                          dager                                                                                                                                                  dag 




9. Hvor mange av de siste 7 dager har du utført fysisk aktivitet i fritiden som har medført    
moderat høy puls i totalt minst 30 minutter? (Bolker på 10 minutters varighet teller, dvs at 3x 
10 minutter fører til 30 minutters aktivitet). 
 
                      Ingen           1 dag          2 dager          3 dager          4 dager         5 dager          6 dager                Hver  
                          dager                                                                                                                                                 dag 
                                                                                                                                                      
 
 
   10. Hvor mange av de siste 7 dager har du utført fysisk aktivitet i fritiden som har medført 
høy puls i minst 20 minutter (sammenhengende)? 
                    
                        Ingen           1 dag           2 dager           3 dager           4 dager          5 dager           6 dager               Hver  
                        dager                                                                                                                                                    dag 
                                                                                                                                                        
 
 
11. Var de siste 7 dagene representative for det vanlige fysiske aktivitetsnivået ditt? 
 
                                                                      Nei, var mer fysisk                                           Nei, var mindre  
                            Ja                                         aktiv enn vanlig                                          fysisk aktiv enn vanlig    
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Kort spørreskjema om kosthold og fysisk aktivitet for 
barnet som er med i CHASE-studien 
 






































Skjemaet består av 3 sider  
og inneholder 




I det følgende spør vi om barnets spisevaner slik de vanligvis er. Vi er klar over at kostholdet varierer 
fra dag til dag. Prøv derfor så godt du kan å gi et ”gjennomsnitt” av barnets spisevaner.  
Ha det siste året i tankene når du svarer. Der du er usikker, anslå svaret. 
 
 
1. Hvor ofte pleier barnet å spise følgende måltider i løpet av en uke? (sett ett kryss for hvert 
måltid) 
 
                                             Aldri/           1 gang       2 ganger       3 ganger       4 ganger        5 ganger        6 ganger       Hver                           









                                                                                                                    
  
                                                                                                                     
  
                                                                                                                    
  




2. Hvor mye drikker barnet vanligvis av følgende drikker? (sett ett kryss for hver drikke)  
(3 glass = ½ liter) 
 
                                                     Drikker            1-3 glass      1-3 glass      4-6 glass      1-3 glass      4-6 glass     7 glass el 
                                            Aldri/sjelden    pr mnd         pr uke          pr uke           pr dag          pr dag        mer pr dag 
 
Helmelk (søt/sur)                                                                                                          
 
Lettmelk (søt/sur)                                                                                                          
 
Ekstra lett lettmelk                                                                                                          
  
Skummet melk (søt/sur)                                                                                                          
 
Appelsinjuice                                                                                                          
   
Saft med sukker                                                                                                          
 
Saft kunstig søtet                                                                                                          
 
Brus med sukker                                                                                                          
   











4. Hvor mange ganger spiser barnet følgende matvarer? (sett ett kryss for hver matvare). 
                                                                           
 
                                                                    Aldri/         1-3           1-3            4-6           1 gang       2 ganger     3 ganger     4 ganger   
                                                                    Sjelden      ganger     ganger       ganger      pr dag        pr dag         pr dag        eller flere  
                                                                                      pr mnd     pr uke       pr uke                                                               pr dag    




























                                                                                                  
      
                                                                                                   
      
                                                                                                   
      
                                                                                                    
      
                                                                                                   
      
                                                                                                   
      
                                                                                                   
      
                                                                                                   
     
                                                                                                   
      
                                                                                                   
      
                                                                                                   
      
                                                                                                   
      
                                                                                                   
      







5. Utenom skoletid/barnehagen: Hvor ofte driver barnet idrett eller mosjonerer så mye at 




Mindre enn en gang i mnd. 
 
1-3 ganger i mnd. 
 
1 gang i uka 
 
2-3 ganger i uka 
 














6. Utenom skoletid/barnehage: Hvor mange timer i uka driver barnet idrett eller mosjonerer 




Omtrent ½ time 
 
Omtrent 1 time 
 
Omtrent 2-3 timer 
 
Omtrent 4-6 timer 
 














7. Utenom skoletid/barnehage: Hvor mange timer per dag pleier barnet å se på TV og/eller 
sitte foran PC’en eller bruker andre spillkonsoller (feks Nintendo Wii, Nintendo DS, 
Playstation, X-box 360)? (sett ett kryss) 
 
Ikke i det hele tatt 
 
Mindre enn en ½ time  
 



















8. Hvilken utdanning har barnets mor og far? (sett ett kryss for høyest fullførte utdannelse hos 




9-årig skole eller kortere 
 
Grunnkurs/ettårig utdannelse utover 9-årig skole 
 
Videregående skole/Gymnas/Yrkesskole (3-årig) 
 
Høyskole- eller universitetsutdanning på 4 år eller mindre 
 
Høyskole- eller universitetsutdanning på mer enn 4 år 
 
Annet 
 
 
Mor
 
 
 
 
 
 
 
 
 
 
 
 
 
Far 
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